# TRANSITION METAL CATALYZED 1,5-SUBSTITUTION REACTIONS OF CONJUGATED ENYNE OXIRANES LEADING TO ALLYLIC HYDROXY SUBSTITUTED VINYLALLENES

A Thesis Submitted to the Graduate School of Engineering and Sciences of İzmir Institute of Technology in Partial Fulfillment of the Requirements for the Degree of

## **DOCTOR OF PHILOSOPHY**

in Chemistry

by MELİH KUŞ

August 2015 İZMİR We approve the thesis of Melih KUŞ

**Examining Committee Members:** 

**Prof. Dr. Levent ARTOK** Department of Chemistry, İzmir Institute of Technology

**Assoc. Prof. Dr. Mustafa EMRULLAHOĞLU** Department of Chemistry, İzmir Institute of Technology

**Prof. Dr. Stephen Thomas ASTLEY** Department of Chemistry, Ege University

**Prof. Dr. Yüksel ŞAHİN** Department of Chemistry, Adnan Menderes University

**Assoc. Prof. Dr. Muhammet Emin GÜNAY** Department of Chemistry, Adnan Menderes University

20 August 2015

**Prof. Dr. Levent ARTOK** Supervisor, Department of Chemistry, İzmir Institute of Technology

**Prof. Dr. Ahmet Emin EROĞLU** Head of the Department of Chemistry **Prof. Dr. Bilge KARAÇALI** Dean of the Graduate School of Engineering and Sciences

# ACKNOWLEDGEMENTS

First of all, I would like to thank my advisor Prof. Dr. Levent ARTOK. This thesis could not have been written without him who not only served as my supervisor but also encouraged and challenged me throughout my academic program. He patiently guided me through the evaluation period of the thesis, never accepting less than my best efforts. It was an honour to study with him. I thank him so much.

Special thanks to Assoc. Prof. Dr. Mustafa EMRULLAHOĞLU, Prof. Dr. Stephen Thomas ASTLEY, Prof. Dr. Yüksel ŞAHİN and Assoc. Prof. Dr. M. Emin GÜNAY for participating as committee member and for reviewing my work.

Additionally, during this work I have collaborated with my colleagues Firat Ziyanak, Doğan Taç, Erman Kıbrıs, İsmet Arınç Aytaç, Ezgi Şule Karagöz and Gürkan Eray Akpınar for whom I have great regard, and I wish to extend my warmest thanks to all those who have helped me with my work at Chemistry Department.

I would like to thank to Dr. Hüseyin Özgener for FT-IR analyses, Assist. Prof. Dr. Muhittin Aygün for X-ray analysis, and Salih Günnaz for NMR analyses

I would like to express my thanks to my family for their motivation, continuous support and prayers. They always supported me for my educational decisions. They have always been by my side whenever I needed them.

At last, thanks to The Scientific and Technological Research Council of Turkey (TUBITAK-210T092) and IZTECH (BAP-2011İYTE31) for financial support.

# ABSTRACT

# TRANSITION METAL CATALYZED 1,5-SUBSTITUTION REACTIONS OF CONJUGATED ENYNE OXIRANES LEADING TO ALLYLIC HYDROXY SUBSTITUTED VINYLALLENES

Transition metal-catalyzed reactions are atom economical and environmentally benign processes, which make them superior to traditional stoichiometric reactions. Transition metal-catalyzed carbonylation reactions of unsaturated systems has become an important methodology for the synthesis of carbonyl containing synthetically valuable compounds.

One of these types of reactions is the alkoxycarbonylation of unsaturated systems over transition metals in the presence of alcohol and under CO atmosphere (Scrivanti, *et. al.* 1998).

Pionering works on palladium-catalyzed alkoxycarbonylation of allylic and propargylic systems with a leaving group at an apropriate positions leading to  $\beta$ , $\gamma$ -unsaturated and allene esters, respectively have been established by several research groups (Tsuji, *et al.* 2004).

Recently, Artok and co-workers developed new methods for the construction of functionalized vinylallene esters via palladium-catalyzed alkoxycarbonylation of 2,4enyne carbonates (Akpınar, *et al.* 2011). After tuning the reaction conditions precisely, the methodology could be improved to allow a high degree of center-to-axial chirality transfer (Karagöz, *et al.* 2014).

Within the context of this study, palladium-catalyzed alkoxycarbonylative 1,5substitution of conjugated enyne oxiranes was also found to provide a diastereoselective route to (*E*)-configured 7-hydroxy-2,3,5-trienoates. The reactions proceeded in a highly stereoselective manner, possibly through sequential formation of  $\pi$ -allylpalladium and  $\sigma$ vinylallenyl palladium complexes. The major diastereomeric form of the product was determined by the configuration of the alkenyl moiety of the substrate.

# ÖZET

# ALLİLİK HİDROKSİ SÜBSTİTÜE VİNİLALLENLERİN OLUŞUMUNA NEDEN OLAN GEÇİŞ METAL KATALİZLİ KONJUGE ENİNOKSİRANLARIN 1,5-SÜBSTİTÜSYON TEPKİMELERİ

Geçiş metal katalizli reaksiyon yöntemleri atom-ekonomik ve çevre dostu olmalarından dolayı klasik stokiyometrik reaksiyon yöntemlerine kıyasla gün geçtikçe daha önemli hale gelmektedirler. Doymamış sistemlerin geçiş metal katalizli karbonilasyon tepkimeleri nitelikli kimyasalların sentezinde sıklıkla kullanılan bir metot haline gelmiştir. Bu bağlamda gerçekleştirilen tepkimelerin bir alt dalı olan alkoksikarbonilasyon tepkimeleri ise karbonil grubu içeren doymamış sistemlerin sentezine, bir metal katalizörü eşliğinde, alkol ve CO gazı altında olanak sağlar (Scrivanti, *et. al.* 1998).

Propargilik ve allilik pozisyonlarında bir ayrılan grup taşıyan yapıların alkoksikarbonilasyon tepkimeleri ile sırasıyla  $\beta$ , $\gamma$ -doymamış ve allen ester oluşturan çalışmaları git gide önem kazanmış ve çeşitli araştırma grupları tarafından başarıyla gerçekleştirilmiştir (Tsuji, *et al.* 2004).

Yakın bir süre önce çalışma grubumuz tarafından 2,4-enin karbonat yapılarının paladyum-katalizli alkoksikarbonilasyon tepkimeleri başarıyla gerçekleştirilmiş ve fonksiyonlandırılmış vinilallen ester içeren yapılar yüksek verimler ile elde edilmiştir (Akpınar, *et al.* 2011). Daha sonra titizlik ile yapılan optimizasyon çalışmaları ile metod daha da geliştirilmiş ve enantiyomerik olarak zenginleştirilmiş 2,4-enin karbonat yapılarına uygulandığında metodun merkezden eksene kiralite transferine olanak sağladığı saptanmıştır (Karagöz, *et al.* 2014).

Bu çalışma kapsamında, 2,4-enin oksiran yapılarının alkoksikarbonilasyon tepkimeleri araştırılmıştır. Geliştirilen metod yüksek verim ve diastereo seçimlilik ile (E)-konfigürasyonuna sahip 7-hidroksi-2,3,5-trienoat yapılarının sentezine olanak sağlamıştır.

# **TABLE OF CONTENTS**

LIST OF FIGURES	ix
LIST OF TABLES	xi
ABBREVIATIONS	. xii
CHAPTER 1. INTRODUCTION	1
CHAPTER 2. LITERATURE WORKS	3
2.1. Palladium(0)-Catalyzed Reactions of Propargyl	
Compounds	3
2.2 Carbonylation Reactions of Propargylic Compounds	
Containing a Leaving Group	6
2.3 Palladium(0)-Catalyzed Reactions of Allylic	
Compounds	9
2.4 Carbonylation Reactions of Propargylic Compounds	
Containing a Leaving Group	. 10
2.5 Synthesis of Vinylallenes	. 14
2.5.1 Synthesis of Vinylallenes with Grignard Reagent	. 14
2.5.2 Synthesis of Vinylallenes with Organocopper	
Reagents	. 15
2.5.3 Palladium(0)-Catalyzed Synthesis of Vinylallene	
with Organozinc Reagent	. 16
2.5.4 Palladium(0)-Catalyzed Synthesis of	
Vinylallenes by N-Tosylhydrazone Salts	. 17
2.5.5 Palladium(0)-Catalyzed Synthesis of Vinylallene	
by Alkenyl Trifluoroborates	. 17
2.5.6 Rhodium(I)-Catalyzed Reaction of the (Z)-Enyne	
Acetate with Organoboronic Acids	. 18
2.5.7 Palladium(0)-Catalyzed Reaction of 2,4-Enyne	
Carbonates with Organoboronic Acids	. 18

2.5.8 Palladium(0)-Catalyzed Alkoxycarbonylation
Reaction of 2,4-Enyne Carbonates
2.5.9 Vinylallenes in Synthesis
CHAPTER 3. EXPERIMENTAL STUDY
3.1. General Procedures for Drying the Solvents
3.2. Synthesis of Substrates
3.2.1. Synthesis of ( <i>Z</i> )-1a
3.2.2. Synthesis of (Z)-1d
3.2.3. Synthesis of (Z)-1i and (Z)-1i'
3.2.4. Synthesis of ( <i>Z</i> )-1m
3.2.5. Synthesis of (Z)-1q and hydroxyl tethered (Z)-
2,4-enyne oxiranes
3.2.6. Synthesis of ( <i>Z</i> )-1b, c, h, k, l, n, o, p, s
3.2.7. Synthesis of ( <i>Z</i> )-1e and ( <i>Z</i> )-1r
3.2.8. Synthesis of ( <i>Z</i> )-1f and ( <i>Z</i> )-1g
3.2.9. Synthesis of ( <i>E</i> )-1b
3.2.10. Synthesis of ( <i>Z</i> )-1t
3.2.11. Synthesis of ( <i>Z</i> )-1j
3.2.12. Carbamate derivatization of 2ba and crystal
growth for X-ray analysis
3.3. Characterization of Reactants
3.4. General Procedure for Carbonylation Reactions
3.5. Characterization of Products
CHAPTER 4. RESULTS AND DISCUSSION
CHAPTER 5. CONCLUSION7
REFERENCES

APPENDICES

APPENDIX A. 1H NMR and 13C NMR SPECTRUMS OF REACTANTS A	AND
PRODUCTS	75
APPENDIX B. MASS SPECTRUMS OF PRODUCTS	

# LIST OF FIGURES

<u>Figure</u>	<b>Page</b>
Figure 2.1. Formation of $\sigma$ -allenylpalladium 1 and propargyl	
palladium 2	
Figure 2.2. Insertion reactions of $\sigma$ -allenylpalladium 1 intermediate	
Figure 2.3. Transmetallation reaction of $\sigma$ -allenylpalladium 1	
intermediate	4
Figure 2.4. Reaction of $\sigma$ -allenylpalladium which involves	
nucleophilic attack.	5
Figure 2.5. Reaction of $\sigma$ -prop-2- ynylpalladium intermediate	5
Figure 2.6. Reaction of propargyl carbonates and oxiranes.	6
Figure 2.7. Pd(0)-catalyzed alkoxycarbonylation of propargyl	
compounds	6
Figure 2.8. Alkoxycarbonylation of propargyl carbonates with	
Pd(OAc)2/phosphine ligand system.	7
Figure 2.9. Alkoxycarbonylation of propargyl carbonates to form 2, 4-	
dienyl carboxylate	7
Figure 2.10. Carbonylation reaction of propargylic mesylate to give	
optically active allenes.	8
Figure 2.11. Carbonylation reaction of optically active propargylic	
phosphates	8
Figure 2.12. Alkoxycarbonylation of propargyl alcohol	8
Figure 2.13. Alkoxycarbonylation of propargyl oxirane.	9
Figure 2.14. Palladium-catalyzed reactions of allylic compounds	10
Figure 2.15. Palladium-catalyzed carbonylation reaction of 3-	
chloroprop-1-ene	11
Figure 2.16. Palladium-catalyzed alkoxycarbonylation of allyl	
carbonates	11
Figure 2.17. Alkoxycarbonylation mechanism of allyl carbonates	12
Figure 2.18. Palladium-catalyzed alkoxycarbonylation of allyl	
phosphates	

Figure 2.19. Palladium-catalyzed alkoxycarbonylation of allyl	
acetates1	.3
Figure 2.20. Palladium-catalyzed alkoxycarbonylation of allyl alcohol 1	.3
Figure 2.21. Palladium-catalyzed alkoxycarbonylation of allyl alcohol 1	.3
Figure 2.22. Palladium-catalyzed nucleophilic reactions of allylic	
oxiranes1	.4
Figure 2.23. Palladium-catalyzed alkoxycarbonylation reactions of	
allylic oxiranes1	.4
Figure 2.24. Reaction of chloro-enynes with Grignard reagents1	.5
Figure 2.25. 1, 5-( $S_N 2^{"}$ )-type Substitution reaction of enyne acetates	
with dialkyl cuprates 1	.5
Figure 2.26. 1, 5-( $S_N 2^{\prime\prime}$ )-type Substitution reaction of enyne oxiranes	
with dialkyl cuprates1	.6
Figure 2.27. Synthesis of vinylallenes by organozinc reagents 1	.6
Figure 2.28. Synthesis of vinylallene by <i>N</i> -tosylhydrazone salt 1	.7
Figure 2.29. Synthesis of vinylallene by alkenyltrifluoroborates 1	.8
Figure 2.30. $Rh(I)$ -catalyzed reaction of the (Z)-enyne acetate with	
organoboronic acids1	.8
Figure 2.31. Palladium-catalyzed reaction of 2, 4-enyne carbonates	
with organoboronic acids1	.9
Figure 2.32. Palladium-catalyzed alkoxycarbonylation reaction of (Z)-	
2, 4-enyne carbonates1	.9
Figure 2.33. Palladium-catalyzed alkoxycarbonylation reaction of $(E$	
and $Z$ )-2, 4-enyne carbonates leading to enantioriched	
vinyl allene derivatives	20
Figure 4.1. X-ray crystallographic structure of the phenylcarbamate	
derivative of 2ba	51
Figure 4.2. Methoxycarbonylation of ( <i>Z</i> )-1t	57
Figure 4.3. The Mechanism of Alkoxycarbonylation of Conjugated	
Enyne Oxiranes6	<u>;</u> 9
Figure 4.4. Methoxycarbonylation of ( <i>Z</i> )-1i	0'

# LIST OF TABLES

Table	Page
Table 4.1. Methoxycarbonylation of Enyne Oxirane (Z)-1a.	60
Table 4.2. The Effect of Ligand on Methoxycarbonylation of (Z)-1ba	62
Table 4.3. Alkoxycarbonylation of Enyne Oxirane (Z)-1a	63
Table 4.4. Alkoxycarbonylation of Enyne Oxiranes	65
Table 4.5. Alkoxycarbonylation of Enyne Oxirane (Z)-10	68

# **ABBREVIATIONS**

		etc.	and other things
Ac	Acetate	equiv.	Equivalent
aq.	Aqueous	g	Grams
Ar	Aryl	h.	Hour(s)
Bu	Butyl	<i>i</i> -Pr	Iso-propyl
BINAP	2,2'- bis(diphenylphosphino)- 1 1'-hinaphthalene	M m	Molar Meta
BIPHEP	2,2'- bis(diphenylphosphino)-	<i>m</i> -CPBA acid	meta-Chloroperbenzoic
_	l,l'-biphenyl	Me	Methyl
Bn	Benzyl	mg	Milligrams
Су	Cyclohexyl	min.	Minutes
dba	Dibenzylideneacetone	mL	Milliliters
DCM	Dichloromethane	μm	Micrometer
DIBALH hydride	Diisobutylaluminum	0	Ortho
DMAP	4-Dimethylaminopyridine	p	Para
DMF	N,N-Dimethylformamide	Pn	Phenyl
dppb	1,4-Bis(diphenylphosphino) butane	<i>p</i> -1s RT	Room temperature
dppe	1,2-Bis(diphenylphosphino) ethane	t	Time
		<i>t</i> -Bu	Tertiary butyl
dppf	1,1'- Bis(diphenylphosphino) ferrocene	TBDMS	Tertiary butyldimethylsilyl chloride
dpph	1,6-Bis(diphenylphosphino) hexane	THF	Tetrahydrofurane
		Ts	Tosyl
DPEphos	Bis[(2- diphenylphosphino)phenyl] ether	Xantphos	4,5- Bis(diphenylphosphino)- 9,9-dimethylxanthene
d.r.	Diastereomeric ratio		
Et	Ethyl		

# **CHAPTER 1**

### **INTRODUCTION**

Allenes are of an important class of organic compounds, which are characterized by two cumulated carbon–carbon double bonds. Biological activity, axially chiral backbone and their presence in many natural products make the allenes crucial materials for organic synthesis.

After the pioneering works in the area of carbonylation type reactions by Roelen and Reppe in 1939 and 1953, respectively, transition metal-catalyzed carbonylation reactions involving the use of carbon monoxide as a reactant have became popular method for building carbonyl containing molecules.

After the first palladium-catalyzed carbonylation reaction of propargylic compounds, bearing a leaving group, reported in 1966 (Tsuji, *et al.* 1995), the palladium-catalyzed alkoxycarbonylation reaction of propargylic derivatives under mild conditions has become an important method for the synthesis of functionalized allene derivatives.

Vinyl-substituted allenes are reactive compounds toward various cycloaddition and cyclization reactions. They exhibit particularly a higher activity and selectivity with Diels-Alder reactions, because their configurational equilibrium is more on the side of scis conformer—a prerequisite for a [4+2] cycloaddition reaction to occur effectively than for 1, 3-dienes (Bond, *et al.* 1990). In spite of their synthetic utility in organic reactions, there are only a few methods that can generate vinylallene structures.

Propargylic carbonates, phosphates, and mesylates having a vinyl functionality can undergo palladium-catalyzed transformations in the presence of a hard or soft nucleophile as a coupling partner to afford vinylallene derivatives (Molander, *et al.* 2006, Ma, *et al.* 2003, Chen, *et al.* 2011).

Also, Artok's research group showed that the palladium-catalyzed alkoxycarbonylation reactions of 2,4-enyne carbonates lead to the formation of 2,3,5-trienoates in high yields (Akpınar, *et al.* 2011, Karagöz, *et al.* 2014).

In this study, we have developed a mild, simple and atom economical method for the diastereoselective synthesis of (E)-configured 7-hydroxy-2,3,5-trionates via palladium-catalyzed alkoxycarbonylative 1,5-substitution reactions of conjugated enyne oxiranes. The reactions proceeded in a highly stereoselective manner, possibly through sequential formation of  $\pi$ -allylpalladium and  $\sigma$ -vinylallenyl palladium complexes. The major diastereometric form of the product is determined by the configuration of the alkenyl moiety of the substrate.

## **CHAPTER 2**

# LITERATURE WORKS

## 2.1. Palladium(0)-Catalyzed Reactions of Propargyl Compounds

The Pd(0)-catalyzed reactions of propargylic compounds proceed through the formation of two intermediates; the  $\sigma$ -allenylpalladiums **1** or the propargylpalladiums **2** (Figure 2.1), (Elsevier, *et al.* 1986).



Figure 2.1. Formation of  $\sigma$ -allenylpalladium **1** and propargylpalladium **2**.

In consideration of the literature, depending on co-reactant types  $\sigma$ -allenylpalladium complexes **1** can undergo three types of transformations.



Figure 2.2. Insertion reactions of  $\sigma$ -allenylpalladium 1 intermediate. (Source: Meijere, et al. 2004)

The first one is the insertion of intermediate **1** into unsaturated bonds of alkenes, alkynes, and carbon monoxide to generate the alkyl-, alkenyl- and acyl palladium intermediates **3**, **4**, and **5**, respectively. These intermediates undergo further transformations to afford synthetically valuable compounds (Figure 2.2), (Meijere, *et al.* 2004).

The second type of transformation proceed through the transmetallation of intermediate **1** with hard nucleophiles such as metal hydride, Grignard, organozinc, organosilane and organoboron reagents to afford the allene derivatives after subsequent reductive elimination (Figure 2.3), (Tsuji, *et al.* 2004).



Figure 2.3. Transmetallation reaction of  $\sigma$ -allenylpalladium **1** intermediate.

And the last type of transformation is the nucleophilic attack of the nitrogen and oxygen containing nucleophiles and soft nucleophiles to the central allenic carbon atom. This nucleophilic attack results in the formation of intermediate **A**, which can be protonated to form alkene derivatives or add a second nucleophile through the formation of  $\pi$ -allylpalladium intermediate, resulting in the formation of alkene derivatives **B** (Figure 2.4).



Figure 2.4. Reaction of  $\sigma$ -allenylpalladium which involves nucleophilic attack. (Source: Meijere, et al. 2004)

In case of propargylpalladium 2 intermediate (Figure 2.5), in the literature two common types of transformations are encountered; hydrogenolysis and  $\beta$ -H elimination (Tsuji, *et al.* 1995).



Figure 2.5. Reaction of  $\sigma$ -prop-2-ynylpalladium intermediate (2).

Pd(0)-catalyzed reactions of propargyl derivatives exhibit different reactivities depending on the substituents on the propargylic positions. Propargyl alcohols are easily available substrates but they are the least reactive species. However, their esters such as acetates, carbonates, and phosphates are very reactive. The main factor of this reactivity difference is the leaving ability of the propargylic substituents. Acetates, carbonates, and phosphates are good leaving groups compared to alcohols.

Propargyl carbonates **8** undergo Pd(0)-catalyzed reactions under mild conditions. The key step of this transformation is the generation of  $\sigma$ -allenyl(methoxy)palladiums **9**. Also alkynyl oxiranes **10** behave like ester derivatives and undergo facile reactions under mild conditions by forming the complex **11** as an intermediate (Figure 2.6).



Figure 2.6. Reaction of propargyl carbonates and oxiranes.

# 2.2 Carbonylation Reactions of Propargylic Compounds Containing a Leaving Group

In Pd(0)-catalyzed alkoxycarbonylation reactions, alkynes substituted with a leaving group at the propargylic positions are frequently used. As discussed in the previous section, the key step of these transformation is the formation of  $\sigma$ -allenylpalladium **1** or **11** intermediates (Tsuji, et al. 1987). Carbon monoxide, (CO), can easily insert into this intermediate to form acyl palladium(II) species which then undergoes nucleophilic addition of alcohol to form ester derivatives. Depending on the reaction conditions mono- and dicarbonylations can take place (Figure 2.7), (Tsuji, *et al.* 1993).



X: OCOOR, OCOR, PO(OR)<sub>2,</sub> Br, Ms

Figure 2.7. Pd(0)-catalyzed alkoxycarbonylation of propargyl compounds.

As an example from the literature, in 1986, Tsuji and co-workers reported the first alkoxycarbonylation reaction of propargyl carbonates in Pd<sub>2</sub>(dba)<sub>3</sub>-CHCl<sub>3</sub>/PPh<sub>3</sub> catalytic system. Secondary and tertiary carbonates having internal or terminal alkyne moieties, yielded desired 2,3-dienyl carboxylate products in good yields (Figure 2.8), (Tsuji, *et al.* 1986).



Figure 2.8. Alkoxycarbonylation of propargyl carbonates with Pd(OAc)<sub>2</sub>/phosphine ligand system. (Source: Tsuji, *et al.* 1986)

Also, they reported that 2,4-dienyl carboxylate was formed instead of allenyl esters if the reaction was performed in ether, and an alcohol was used as a reactant (Figure 2.9), (Tsuji, *et al.* 1986).



Figure 2.9. Alkoxycarbonylation of propargyl carbonates to form 2, 4-dienyl carboxylate. (Source: Tsuji, *et al.* 1986)

The carbonylation of chiral propargyl mesylates in the presence of Pd(PPh<sub>3</sub>)<sub>4</sub> and under CO and in the presence of water, yielded allenic acids in good yields which were then converted stereospecifically to butenolides by treatment with AgNO<sub>3</sub>. A good transfer of chirality was observed, although racemization occurred by the carbonylation of the corresponding propargyl carbonate derivative (Figure 2.10), (Marshall, *et al.* 1997).



Figure 2.10. Carbonylation reaction of propargylic mesylate to give optically active allenes. (Source: Marshall, *et al.* 1997)

In addition, a good transfer of chirality was observed in the carbonylation reaction of propargyl phosphates in the Pd(OAc)<sub>2</sub>/1,6-bis(diphenylphosphino)hexane catalytic system and thus optically active 2,3-dienoates could be obtained with high enantiomeric excesses (Figure 2.11), (Tsuji, *et al.* 1995).



Figure 2.11. Carbonylation reaction of optically active propargylic phosphates. (Source: Tsuji, et al. 1995)

Propargyl alcohols are less reactive than their esters. Carbonylation of the tertiary propargyl alcohol at relatively harsh reaction conditions such as high CO pressures and temperatures was able to provide the formation of 2(5H)-furanones (Figure 2.12), (Alper, *et al.* 1997).



Figure 2.12. Alkoxycarbonylation of propargyl alcohol. (Source: Alper, *et al.* 1997)

The Pd(0)-catalyzed reaction of propargylic oxirane substrates with alcohols under CO atmosphere also generates hydroxy-functionalized allenic esters in good yields (Figure 2.13).



Figure 2.13. Alkoxycarbonylation of propargyl oxirane. (Source Tsuji, *et al.* 2004)

## **2.3 Palladium(0)-Catalyzed Reactions of Allylic Compounds**

Allylic compounds substituted with leaving groups such as acetates, carbonates, phosphates *etc.* play significantly important role in synthetic organic chemistry due to formation of  $\pi$ -allyl palladium complexes with palladium catalysts. Further transformation of this complex with various types of coupling partners offer many synthetically useful methods for the synthesis of valuable chemicals.

In 1965, Tsiju, *et al.* reported the first formation of  $\pi$ -allyl palladium complex from allylic compounds. They described the electrophilic property of  $\pi$ -allyl palladium complex and regeneration of the Pd(0) after coupled with pronucleophiles which offers the possibility of a catalytic process (Figure 2.14).



Figure 2.14. Palladium-catalyzed reactions of allylic compounds. (Source: Tsuji, *et al.* 2004)

# 2.4 Carbonylation Reactions of Propargylic Compounds Containing a Leaving Group

In 1964, Tsuji, *et al.* showed that  $\beta$ , $\gamma$ -unsaturated esters can be prepared by carbonylation of allylic compounds. According to researchers,  $\pi$ -allylpalladium chloride can be converted to  $\beta$ , $\gamma$ -ester derivatives under CO pressures in alcohols with PdCl<sub>2</sub> as the catalyst (Figure 2.15).



Figure 2.15. Palladium-catalyzed carbonylation reaction of 3-chloroprop-1-ene. (Source: Tsuji, *et al.* 1964)

In 1984, Tsuji, *et al.* described the synthesis of  $\beta$ , $\gamma$ -unsaturated ester derivatives by the reaction of allylic carbonates and alcohol in Pd(OAc)<sub>2</sub>/PPh<sub>3</sub> catalytic system under mild reaction conditions (Figure 2.16).



Figure 2.16. Palladium-catalyzed alkoxycarbonylation of allyl carbonates. (Source: Tsuji, *et al.* 1984)

According to the proposed reaction mechanism,  $\pi$ -allylpalladium alkoxide intermediate can be formed from the the oxidative addition of palladium catalyst to an allyl carbonate and subsequent decarboxylation. The following carbon monoxide insertion reductive elimination steps lead to formation of  $\beta$ , $\gamma$ -unsaturated ester derivatives and regeneration of the Pd(0) species (Figure 2.17).



Figure 2.17. Alkoxycarbonylation mechanism of allyl carbonates.

In 1993, Murahashi, *et al.* showed that allyl phosphate derivatives are suitable reagents for Pd(0)-catalyzed carbonylation reactions, although harsh reaction conditions were required. The reaction was carried out over the Pd<sub>2</sub>(dba)<sub>3</sub>-CHCl<sub>3</sub>/PPh<sub>3</sub> catalytic system at high CO pressures and temperatures to obtain the  $\beta$ , $\gamma$ -unsaturated esters with high yields. It was noted that isomerization of the double bond was occurred depending on the substituents on the allyl phosphate derivatives (Figure 2.18).



Figure 2.18. Palladium-catalyzed alkoxycarbonylation of allyl phosphates. (Source: Murahashi, *et al.* 1993)

They also showed that  $\beta$ , $\gamma$ -unsaturated esters could be synthesized by the reaction of allyl acetates at high CO pressures and temperatures. The reaction was carried out over the Pd<sub>2</sub>(dba)<sub>3</sub>-CHCl<sub>3</sub>/PPh<sub>3</sub> catalytic system, and NaBr was used as a co-catalyst (Figure 2.19). NaBr accelerates the reaction because, after the generation of  $\pi$ allylpalladium acetate complex ligand exchange of acetate with bromide took place, this making the CO insertion more facile (Figure 2.19), (Murahashi, *et al.* 1993).



Figure 2.19. Palladium-catalyzed alkoxycarbonylation of allyl acetates.. (Source: Murahashi, *et al.* 1993)

Harsh reaction conditions were needed for less reactive allylic alcohols. However, carbonylation of allylic alcohols proceeds smoothly in the presence of phenol as a nucleophile. 4-Phenyl-3-butenoate was obtained in a good yield from cinnamyl alcohol under 5 atm of CO at 100 °C with Pd<sub>2</sub>(OAc)<sub>2</sub>/PPh<sub>3</sub> catalytic system (Satoh, *et al.* 1997).



Figure 2.20. Palladium-catalyzed alkoxycarbonylation of allyl alcohol. (Source: Satoh, *et al.* 1997)

Allyl alcohol was carbonylated under a high pressure of  $CO_2$  (50 atm) and CO (50 atm) mixture at 110 °C in dioxane to provide 2-butenoic acid as the major product and 3-butenoic acid as the minor product (Sakamoto, *et al.* 1996).



Figure 2.21. Palladium-catalyzed alkoxycarbonylation of allyl alcohol. (Source: Sakamoto, *et al.* 1996)

Pd(0)-catalyzed reactions of alkenyloxiranes afford either 1,4-adducts or 1,2adducts. 1,4-Adducts are mainly obtained under usual conditions due to the electronic effect of the epoxide oxygen atom (Figure 2.22), (Tsuji, *et al.* 1981, Trost, *et al.* 1981).



Figure 2.22. Palladium-catalyzed nucleophilic reactions of allylic oxiranes.

 $\beta$ , $\gamma$ -Unsaturated  $\delta$ -hydroxyesters are obtained by regioselective carbonylation of isoprene oxide in EtOH using a ligand-free Pd catalyst at room temperature under high CO pressure (30 atm). (Figure 2.23), (Shimizu, *et al.* 1993).



Figure 2.23. Palladium-catalyzed alkoxycarbonylation reactions of allylic oxiranes. (Source: Shimizu, *et al.* 1993)

#### 2.5 Synthesis of Vinylallenes

Vinylallenes are reactive compounds toward various cycloaddition and cyclization reactions. They exhibit particularly higher activity and selectivity with Diels-Alder reactions, because their configurational equilibrium is more on the side of s-*cis* conformer -a prerequisite for a [4+2] cycloaddition reaction to occur effectively-than for 1, 3-dienes (Bond, *et al.* 1990).

#### 2.5.1 Synthesis of Vinylallenes with Grignard Reagent

In 1972, Gore, *et al.* developed a method for the synthesis of vinyl substituted allenes by the reactions of 1-chloro-2-en-4-ynes with methylmagnesium iodide and trimethylsilylmagnesium chloride in moderate to good yields (Figure 2.24). The method was just limited to methylmagnesium iodide and trimethylsilylmagnesium chloride, other Grignard reagents completely failed to yield desired vinylallene derivatives.



Figure 2.24. Reaction of chloro-enynes with Grignard reagents. (Source: Gore, et al. 1972)

#### 2.5.2 Synthesis of Vinylallenes with Organocopper Reagents

In 1999, Krause, *et al.* developed a regioselective  $1,5-(S_N2'')$ -type reaction of (*E*)-2, 4-enyne acetates with various lithium dialkylcuprates affording the vinylallenes exclusively. However, this method afforded the desired vinylallene structures as a mixture of *E*- and *Z*- isomers. Moreover, the method was not suitable for aryl- or alkenyl lithium cuprates.



Figure 2.25. 1, 5-(S<sub>N</sub>2")-type Substitution reaction of enyne acetates with dialkyl cuprates. (Source: Krause, et al. 1999)

They also applied their methodology to (E)-2,4enyne oxirane substrates, which were treated with Me<sub>2</sub>CuLi LiI or *t*-Bu<sub>2</sub>CuLi LiCN. The substrate reacted cleanly with the *tert*-butylcuprate to afford the alkylated vinylallene with a primary hydroxyl group, whereas its reaction with the lithium dimethylcuprate reagent proceeded without coupling and led to exclusive reduction to a vinylallene.



Figure 2.26. 1, 5-( $S_N 2^{"}$ )-type Substitution reaction of enyne oxiranes with dialkyl cuprates. (Source: Krause, *et al.* 1999)

# 2.5.3 Palladium(0)-Catalyzed Synthesis of Vinylallene with Organozinc Reagent

In 2003, Ma, *et al.* showed that vinyl allene structures can be formed by the palladium-catalyzed coupling reaction of propargyl mesylates with alkoxycarbonylethenyl zinc complexes with excellent yields in the presence of [{PdCl( $\pi$  -C<sub>3</sub>H<sub>5</sub>)}<sub>2</sub>]/2-diphenylphosphino-2'-hydroxy-1,1'-binaphthalene (L) catalytic system under mild conditions (Figure 2.27).



Figure 2.27. Synthesis of vinylallenes by organozinc reagents. (Source: Ma, et al. 2003)

## 2.5.4 Palladium(0)-Catalyzed Synthesis of Vinylallenes by N-Tosylhydrazone Salts

In 2011, Chen, *et al.* reported that diazo compounds generated *in-situ* from *N*-tosylhydrazone salts in the presence of a base, behave as a nucleophile and react with the propargylic carbonates to form vinylallene structures in the presence of  $[Pd_2(dba)_3]$  (Figure 2.28).



Figure 2.28. Synthesis of vinylallene by *N*-tosylhydrazone salt. (Source: Chen, *et al.* 2011)

# 2.5.5 Palladium(0)-Catalyzed Synthesis of Vinylallene by Alkenyl Trifluoroborates

In 2006, Molender, *et al.* reported Pd(0)-catalyzed cross-coupling reaction of enantio-enriched propargylic carbonates and phosphates with alkenyltrifluoroborates. The method allowed center-to-axial chirality transfer and the desired vinylallene structures were synthesized in good enantiomeric excesses (Figure 2.29).



Figure 2.29. Synthesis of vinylallene by alkenyltrifluoroborates. (Source: Molander, *et al.* 2006)

# 2.5.6 Rhodium(I)-Catalyzed Reaction of the (Z)-Enyne Acetate with Organoboronic Acids

In 2011, Üçüncü, *et al.* reported that Rh(I)-catalyzed reaction of (*Z*)-2,4-enyne acetates with organoboronic acids afforded vinylallenes. The reaction is suitable for arylboronic acids having both electron-withdrawing or -donating groups (Figure 2.30).



Figure 2.30. Rh(I)-catalyzed reaction of the (Z)-enyne acetate with organoboronic acids. (Source: Üçüncü, *et al.* 2011)

## 2.5.7 Palladium(0)-Catalyzed Reaction of 2,4-Enyne Carbonates with Organoboronic Acids

Üçüncü, *et al.* also (2011), showed that arylboronic acids having different electron deficient or electron donating substituents are good coupling partner for Pd(0)-catalyzed reaction of both (*E*)- and (*Z*)-2,4-enyne carbonates, yielding exclusively the (*E*)- configured vinylallene derivatives (Figure 2.31).



Figure 2.31. Palladium-catalyzed reaction of 2, 4-enyne carbonates with organoboronic acids. (Source: Üçüncü, *et al.* 2011)

### 2.5.8 Palladium(0)-Catalyzed Alkoxycarbonylation Reaction of 2,4-Enyne Carbonates

In 2011, Akpinar, *et al.* showed for the first time that conjugated (*Z*)-2,4-enyne derivatives bearing a carbonate as a leaving group at the allylic moiety underwent Pd(0)-catalyzed reaction to lead 2,3,5-trienoate products in high yields (Figure 2.32).



Figure 2.32. Palladium-catalyzed alkoxycarbonylation reaction of (Z)-2, 4-enyne carbonates. (Source: Akpınar, *et al.* 2011)

The reaction conditions were also applied to an enantio-enriched (Z)-2, 4-enyne carbonates. It was found that the reaction proceeded with complete racemization. But after tuning the reaction parameters, moderate to good transfer of chirality was observed depending on the olefin geometry and substituents on the alkyne moiety (Figure 2.32), (Karagöz, *et al.* 2014).



Figure 2.33. Palladium-catalyzed alkoxycarbonylation reaction of (*E* and *Z*)-2, 4-enyne carbonates leading to enantio-enriched vinylallene derivatives. (Source: Karagöz, *et al.* 2014)

### 2.5.9 Vinylallenes in Synthesis

Vinylallenes are valuable dienophiles in Diels-Alder reactions. As an example from the literature, Krause, *et al.* showed that vinylallenes reacted with maleic anhydride in refluxing toluene within 30 h to provide cycloadduct exclusively (Krause, *et al.* 1996).



Figure 2.34. Diels-Alder reactions of vinyallenes. (Source: Krause, et al. 1996)

Vinylallenes are also good reactants for varios cycloisomerization reactions. In 2006, Toste, *et al.* developed a gold(I)-catalyzed cycloisomerization of vinyl allenes for the synthesis of cyclopentadienes. The mild reaction conditions of this gold(I)-catalyzed carbon–carbon bond-forming reaction provide a regiospecific method for the synthesis of highly functionalized cyclopentadienes.



Figure 2.35. Gold-catalyzed cycloisomerization reactions of vinylallenes. (Source: Toste, *et al.* 2006)

Also, Iwasawa, et al. developed a PtCl<sub>2</sub>-catalyzed preparation of highly substituted cyclopentadiene derivatives from 1,2,4-trienes. This reaction proceeds under mild conditions to afford a variety of well-defined, highly substituted cyclopentadienes effectively.



Figure 2.36. Platinium-catalyzed cycloisomerization reactions of vinylallenes. (Source: Iwasawa, *et al.* 2006)

# **CHAPTER 3**

## **EXPERIMENTAL STUDY**

#### **3.1. General Procedures for Drying the Solvents**

THF, DMF, and DCM solvents were all purified by a solvent purification system. Et<sub>2</sub>O was distilled from benzophenone-ketyl under argon prior to use. Methanol and ethanol were dried over Mg turnings in the presence of iodine and stored on molecular sieve 3Å under Ar. 1-Propanol and 2-propanol were dried first by stirring over anhydrous CaO followed by refluxing over Mg turnings in the presence of iodine. 1-Butanol was dried first by stirring over anhydrous MgSO<sub>4</sub> and then refluxed over Mg turnings in the presence of iodine. *tert*-BuOH was stirred over CaH<sub>2</sub> (5% w/v), distilled, and stored on molecular sieve 3Å under Ar.

#### 3.2. Synthesis of Substrates

Syntheses of all enyne oxirane starting materials (1) were performed under Ar gas and purification of all synthesized molecules was performed by column chromatography on silica gel. Silica gel material used for the purification of enyne oxirane substrates had a particle size range of 60-200 mesh and treated by NEt<sub>3</sub> before use. It must be noted that the column chromatography of the substrate 1 on an untreated silica gel always resulted in decomposition. All other column purifications were performed on silica gel 60 (35-70  $\mu$ m). All substrates appeared either colorless or pale yellow oils. The Pd<sub>2</sub>(dba)<sub>3</sub>-CHCl<sub>3</sub> complex was synthesized in the laboratory (Ukai, *et al.* 1974).

#### **3.2.1.** Synthesis of (Z)-1a



To the mixture of commercially available, (Z)-pent-2-en-4-yn-1-ol (**S1**) (1.92 g, 20 mmol) and 3,4-dihydropyran (2.2 mL, 24 mmol) was added *p*-toluenesulfonic acid (44 mg, 0.02 mmol) and then stirred for 45 min at room temperature (RT). Then, the mixture was diluted with 40 mL of dry THF under Ar and cooled to -78 °C. At that temperature, 24 mmol of BuLi (1.6 M in hexane, 15 mL) was added dropwise via a syringe. After stirring the reaction mixture for 1 h at 0 °C, butyl bromide (4.3 mL, 40 mmol) was added and the mixture was stirred for 5 days at reflux. The reaction was quenched by the addition of saturated NH<sub>4</sub>Cl(*aq*) solution and the reaction solution was extracted with Et<sub>2</sub>O. The organic phase was washed with water, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was used in the following step without any other purification (Betzer, *et al.* 1997).

To a solution of the preceding crude compound (S3) in methanol (60 mL) ptoluenesulfonic acid (1.2 g, 6 mmol) was added and the resulting solution was stirred at RT for 45-60 min. Then, triethylamine was added (1.8 mL), and the solution was concentrated under reduced pressure. The mixture was taken into DCM and washed with water. The combined extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. Purification by column chromatography on silica gel gave the enynol S4 (hexane-EtOAc, yield: 2.43 g, 80%), (Ukai, *et al.* 1974).

To the solution of **S4** ( $\approx$ 17 mmol) in 60 mL of dry diethyl ether, activated MnO<sub>2</sub> (30 g, 0.3 mol) was added, and the mixture was stirred overnight at RT. After filtration through Celite, the solution was concentrated under reduced pressure. The crude aldehyde (**S5**) was used in the next step (Betzer, *et al.* 1997).



A hexane solution of BuLi (4.8 mL, 12 mmol, 2.5 M) was added dropwise to a solution of isopropyl(triphenyl)phosphonium iodide (4.32 g, 10 mmol) in THF (30 mL) at 0 °C, and stirred for further 1 h. The enyne aldehyde **S5** (1.8 g, 12 mmol), was added dropwise to the resulting mixture and stirred for 1 h at RT. The reaction was quenched by the addition of saturated NH<sub>4</sub>Cl(*aq*) solution, and the organic layer was extracted with diethyl ether. The combined extracts were dried over MgSO<sub>4</sub>, and chromatographed on a silica gel column to obtain pure **S3a** (hexane/EtOAc, yield: 1.65 g, 78%), (Ming-Yuan, *et al.* 2004).

To a solution of **S6** (352 mg, 2 mmol) in DCM (30 mL) was added 12 mL solution of Na<sub>2</sub>CO<sub>3</sub>(*aq*) (25%) followed by 3.4 mmol (587 mg) *m*-chloroperbenzoic acid dropwise at 0  $^{\circ}$ C. The mixture was stirred at same temperature and monitored with TLC until the reactant was consumed completely. At the end of the epoxidation process, the mixture was extracted with DCM, dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude mixture was chromatographed on NEt<sub>3</sub>-pretreated short silica gel column which afforded the enyne oxirane (*Z*)-**1a** as a colorless oil (hexane-EtOAc, yield: 269 mg, 70%).

#### 3.2.2. Synthesis of (Z)-1d


To a solution of NaH (525 g, 22 mmol) in THF (50 mL) was added triethyl phosphonoacetate (4.8 mL, 24 mmol) at 0 °C, and the mixture stirred 1 h at RT. Subsequently, to the reaction mixture was added **S5** (3 g, 20 mmol) dropwise at -78 °C and stirred for 1 h at RT. The reaction was terminated by the addition of aqueous NH<sub>4</sub>Cl(*aq*) solution and extracted with Et<sub>2</sub>O. The organic layer was dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure to give E/Z isomer 95:5 isomeric ratio. The crude mixture was purified on silica gel column to obtain **S7** in pure isomeric form (hexane-EtOAc, yield: 3.17 g, 72%), (Urabe, *et al.* 1997).

A DIBALH (44 mL, 44 mmol, 1.0 M in cyclohexane) solution was added dropwise to the solution of **S7** (3.85 g, 17.5 mmol) in DCM (120 mL) at -78 °C. After the reaction mixture was stirred for 4 h at the same temperature, 1 M HCl(*aq*) solution was added before extracting with DCM. The organic layers were combined, washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude mixture was subjected to silica gel column chromatography to purify the corresponding **S8** compound (hexane-EtOAc, yield: 2.65 g, 85%), (Kajikawa, *et al.* 2009).

The epoxidation of **S8** (356 mg, 2 mmol) and isolation of the product (*Z*)-1d was performed as specified for (*Z*)-1a (hexane-EtOAc, yield: 233 mg, 60%).

## 3.2.3. Synthesis of (Z)-1i and (Z)-1i'



1-Hexyne (2.3 mL, 20 mmol) was added dropwise to a solution of BBr<sub>3</sub> (22 mL, 22 mmol, 1 M) in dry DCM at -78 °C. The mixture was allowed to warm to ambient temperature, and stirred for 1 h. The reaction mixture was re-cooled to -78 °C and a solution of 2, 3-dimethylbutan-2,3-diol (2.84g, 24 mmol) in dry DCM (20 mL) was added dropwise. Following this addition, the mixture was warmed to ambient temperature and stirred for 1 h. Then, the mixture was quenched by brine and extracted with DCM. The combined organic layers were dried over MgSO<sub>4</sub>, filtered and evaporated. The residue was purified on silica gel column to afford **S9** as a colorless oil (hexane-EtOAc, yield: 3.57 g, 62%), (Wang, *et all.* 2009).

To a stirred solution of **S9** (4.64 g, 16 mmol) and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (1 mol%, 112 mg, 0.16 mmol) in dry THF (20 mL) was added a solution of 1-hexynylzinc chloride, which was generated by treatment of 1-hexyne (1.6 g, 19.2 mmol) with BuLi (8.5 mL, 20.7 mmol, 2.5 M in hexane) in dry THF (20 mL) for 30 min at -78°C and following treatment with ZnCl<sub>2</sub> (2.72 g, 19.2 mmol) for 30 min at 0°C. The resultant reaction mixture was stirred at RT for 1 h before quenching by 0.5 M HCl(*aq*). The content of the reaction medium was extracted with ether, washed with saturated NaHCO<sub>3</sub>(*aq*) and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified on silica gel column to afford **S10** as a colorless oil (hexane-EtOAc, yield: 3.9 g, 84%), (Wang, *et all.* 2009).

A mixture of  $Pd_2(dba)_3$  (137 mg, 0.15 mmol, 3 mol % of Pd), AsPh<sub>3</sub> (184 mg, 0.6 mmol, 6 mol % of As), and 15 mL of 1 M KOH(*aq*) in 50 mL of THF was cooled to 0 °C before the addition of the compound **S10** (2.9 g, 10 mmol). Then, a THF solution (10 mL) of *trans*- (Stille, *et al.* 1987) or *cis*-1-iodo-1-hexene (Denmark, *et al.* 2005) (2.52 g, 12 mmol), which were synthesized according to the literature procedures, was added dropwise and the reaction stirred for 30 min at RT. After the completion of the reaction, water was added to the resulting mixture before extracting with ether. The combined extracts were dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified on silica gel column to afford **S11** or **S11'** as yellowish oil products (hexane-EtOAc, yield of **S11**: 1.89 g, 77%; yield of **S11'**: 1.25 g, 51%), (Fang, *et al.* 2010).

To a solution of **S11** or **S11'** (492 mg, 2 mmol) in DCM (30 mL) was added 12 mL solution of Na<sub>2</sub>CO<sub>3</sub>(*aq*) (25%) followed by 587 mg of *m*-CPBA (3.4 mmol) at 0 °C. The mixture was stirred at the same temperature and monitored with TLC until the reactant was consumed completely. At the end of the epoxidation process, the mixture

was extracted with DCM, dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude mixture was chromatographed on NEt<sub>3</sub>-pretreated short silica gel column which afforded the enyne oxirane (*Z*)-**1i** or (*Z*)-**1i**' in about 85% purities as pale yellow oil products (hexane-EtOAc, yield of (*Z*)-**1i**: 300 mg, 57%; yield of (*Z*)-**1i**': 158 mg, 30%).

### **3.2.4.** Synthesis of (*Z*)-1m



To the mixture of commercially available, (*Z*)-pent-2-en-4-yn-1-ol (**S1**) (1.92 g, 20 mmol) in 80 mL of dry diethyl ether, 37 g of activated  $MnO_2$  (0.4 mol) was added, and the mixture was stirred overnight at RT. After filtration through Celite, the solution was concentrated under reduced pressure. The crude aldehyde was used in the next step (Betzer, *et al.* 1997).

To a solution of NaH (525 g, 22 mmol) in THF (50 mL) was added triethyl phosphonoacetate (4.8 mL, 24 mmol) at 0 °C, and the mixture stirred 1 h at RT. Subsequently, to the reaction mixture was added **S12** (1.88 g, 20 mmol) dropwise at -78 °C and stirred for 1 h at RT. The reaction was terminated by the addition of aqueous NH<sub>4</sub>Cl(*aq*) solution and extracted with Et<sub>2</sub>O. The organic layer was dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure to give E/Z isomer 95:5 isomeric ratio. The crude mixture was purified on silica gel column to obtain **S13** in pure isomeric form (hexane-EtOAc, yield: 2.3 g, 70%), (Urabe, *et al.* 1997).

A DIBALH (44 mL, 44 mmol, 1.0 M in cyclohexane) solution was added dropwise to the solution of **S13** (2.87 g, 17.5 mmol) in DCM (120 mL) at -78 °C. After the reaction mixture was stirred for 4 h at the same temperature, 1 M HCl(*aq*) solution was added before extracting with DCM. The organic layers were combined, washed with

brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude mixture was subjected to silica gel column chromatography to purify the corresponding **S14** compound (hexane-EtOAc, yield: 1.81g, 85%), (Kajikawa, *et al.* 2009).

The epoxidation of **S14** (244 mg, 2 mmol), isolation of the product **S15**, methylation of the pendant hydroxyl group of **S15** (166 mg, 1.2 mmol), and isolation of the product (*Z*)-1m were performed as specified for (*Z*)-1a and (*Z*)-1d, respectively, (hexane-EtOAc, yield of **S15**: 166 mg, 60%; yield of (*Z*)-1m: 144 mg, 87%).

## **3.2.5.** Synthesis of (Z)-1q and hydroxyl tethered (Z)-2,4-enyne oxiranes



To a solution of alkynoic ester **S16** (40 mmol) and acetic acid (240 mmol, 13.8 mL or 512 mmol, 20.8 mL when **S16** is ethyl 4, 4-dimethylpent-2-ynoate and ethyl 3-cyclohexylpropiolate) was added sodium iodide (9.6 g, 64 mmol or 19.2 g, 128 mmol when **S23** is ethyl 4, 4-dimethylpent-2-ynoate and ethyl 3-cyclohexylpropiolate) and stirred for 3 h at 115 °C. After completion of the reaction, the brown mixture was transferred while hot to a separatory funnel containing water (10 mL/mmol of the ester substrate). The reaction flask was washed with a mixture of water (5 mL) and diethyl ether (30 mL/mmol of the ester substrate). The washings were combined in a separatory funnel. The phases were separated and the aqueous phase was extracted with diethyl ether.

The combined organic phases were treated sequentially with saturated aqueous NaHCO<sub>3</sub>(*aq*), Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>(*aq*) (1 M), and brine and then dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The product was purified by column chromatography on silica gel (hexane-EtOAc, yields;  $R^2$ = H, 7.6 g, 84%;  $R^2$ = Me, 8.4 g, 87%;  $R^2$ = t-Bu, 9.6 g, 85%;  $R^2$ = Cy, 10.6 g, 86%), (Piers, *et al.* 1994).

A mixture of **S17** (30 mmol),  $PdCl_2(PPh_3)_2$  (210.6 mg, 0.3 mmol, 1% mol of Pd), and CuI (29 mg, 0.15 mmol, 0.5% mol of Cu) in 140 mL of Et<sub>3</sub>N was stirred for 10 min at RT under Ar, and then, to this mixture was added a terminal alkyne (36 mmol). The mixture was stirred at RT for 3h. At the end of the reaction, water was added to the resulting mixture and then extracted with Et<sub>2</sub>O. The combined organic layers were dried over MgSO<sub>4</sub>. The solvent was evaporated in vacuo and the product **S18** was purified by column chromatography on silica gel (hexane-EtOAc, yields: R<sup>1</sup>= Bu, R<sup>2</sup>= H, 4.97 g, 92%; R<sup>1</sup>= Ph, R<sup>2</sup>= Me, 5.97 g, 93%; R<sup>1</sup>= Cy, R<sup>2</sup>= Me, 5.94 g, 90%; R<sup>1</sup>= *t*-Bu, R<sup>2</sup>= Me, 4.95 g, 85%; R<sup>1</sup>= Bu, R<sup>2</sup>= t-Bu 6.23 g, 88%, R<sup>1</sup>= Bu, R<sup>2</sup>= Cy, 6.21 g, 79%).

A DIBALH (~3 eq, 1.0 M in cyclohexane) solution was added dropwise to the solution of **S18** in DCM (~6 mL/mmol **S18**) at -78 °C. After the reaction mixture was stirred for 4 h at the same temperature, 1 M HCl(*aq*) solution was added before extracting with DCM. The organic layers were combined, washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude mixture was subjected to silica gel column chromatography to purify the corresponding **S19** compound (hexane-EtOAc; yields of **S19**: R<sup>1</sup>= Bu, R<sup>2</sup>= H, 3.14 g, 91%; R<sup>1</sup>= Bu, R<sup>2</sup>= Cy, 4.89 g, 89%; R<sup>1</sup>= Cy, R<sup>2</sup>= Me, 3.60 g, 81%; R<sup>1</sup>= *t*-Bu, R<sup>2</sup>= Me, 3.57 g, 94%; R<sup>1</sup>= Bu, R<sup>2</sup>= *t*-Bu, 4.2 g, 88%; R<sup>1</sup>= Ph, R<sup>2</sup>= Me, 3.87 g, 90%), (Kajikawa, *et al.* 2009).

To the solution of **S19** ( $\approx$ 20 mmol) in 70 mL of dry diethyl ether, activated MnO<sub>2</sub> (35.1 g, 0.35 mol) was added, and the mixture was stirred overnight at RT. After filtration through Celite, the solution was concentrated under reduced pressure. The crude aldehyde (**S20**) was used in the next step (Betzer, *et al.* 1997).

To a solution of NaH (1.1 eq) in THF (2.5 mL/mmol **S20**) was added triethyl phosphonoacetate (1.2 eq) at 0 °C and the mixture stirred for 1 h at RT. Subsequently, to the reaction mixture was added **S20** (6.5-10 mmol) dropwise at -78 °C, and stirred for 1 h at RT. The reaction was terminated by the addition of saturated NH<sub>4</sub>Cl(*aq*) and extracted with Et<sub>2</sub>O. The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to obtain **S21** with E/Z isomeric ratios varying in the range of 97:3 to 95:5 (Urabe, *et al.* 1997). The crude mixture was purified on silica gel column (hexane-

EtOAc) to obtain **S21** in pure isomeric form (yields of **S21**  $R^1$ = Bu,  $R^2$ = H, 1.48 g, 72%;  $R^1$ = Bu,  $R^2$ = Cy, 1.4 g, 68%;  $R^1$ = Cy,  $R^2$ = Me, 1.97 g, 80%;  $R^1$ = *t*-Bu,  $R^2$ = Me, 1.80 g, 82%;  $R^1$ = Bu,  $R^2$ = *t*-Bu, 2.12 g, 81%;  $R^1$ = Ph,  $R^2$ = Me, 2.04 g, 85%).

A DIBALH (~3 eq, 1.0 M in cyclohexane) solution was added dropwise to the solution of **S21** in DCM (~6 mL/mmol **S21**) at -78 °C. After the reaction mixture was stirred for 4 h at the same temperature, 1 M HCl(*aq*) solution was added before extracting with DCM. The organic layers were combined, washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude mixture was subjected to silica gel column chromatography to purify the corresponding **S22** compound (hexane-EtOAc; yields of **S22**: R<sup>1</sup>= Bu, R<sup>2</sup>= H, 1.12 g, 95%; R<sup>1</sup>= Bu, R<sup>2</sup>= Cy, 1.1 g, 94%; R<sup>1</sup>= Cy, R<sup>2</sup>= Me, 1.55 g, 95%; R<sup>1</sup>= *t*-Bu, R<sup>2</sup>= Me, 1.39 g, 95%; R<sup>1</sup>= Bu, R<sup>2</sup>= *t*-Bu, 1.6 g, 90%; R<sup>1</sup>= Ph, R<sup>2</sup>= Me, 1.6 g, 92%), (Kajikawa, *et al.* 2009).

The epoxidation of **S22** (2 mmol) and isolation of the corresponding **S23** products were performed as specified for (*Z*)-**1a** (yields of **S23**:  $R^1$ = Bu,  $R^2$ = H, 0.19 g, 55%;  $R^1$ = Bu,  $R^2$ = Cy, 0.26 g, 49%;  $R^1$ = Cy,  $R^2$ = Me, 0.25 g, 57%;  $R^1$ = *t*-Bu,  $R^2$ = Me, (*Z*)-**1q**, 0.25 g, 65%;  $R^1$ = Bu,  $R^2$ = *t*-Bu, 0.24 g, 50%;  $R^1$ = Ph,  $R^2$ = Me, 0.26 g, 60%).

## **3.2.6.** Synthesis of (*Z*)-1b, c, h, k, l, n, o, p, s



As for the alkylation of the pendant hydroxyl group of **S23**, a suspension of sodium hydride (1.1 eq) in DMF (1 mL) was added to a solution of **S23** (1 mmol) in DMF (1 mL/mmol **S23**) at -20 °C. The mixture was stirred for further 30 min before the addition of methyl iodide (1.2 eq) or benzyl bromide (1.2 eq). The mixture was stirred for 4 h at the same temperature and then the reaction was terminated by the addition of MeOH (5 mL) and brine (5 mL), and extracted with DCM. The combined extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude mixture was subjected to column chromatography over NEt<sub>3</sub>-pretreated short silica gel column to

afford the corresponding alkoxy-substituted enyne oxirane products as colorless oil (hexane-EtOAc, yields: (*Z*)-**1b**, 0.18 g, 87%; (*Z*)-**1c**, 0.22 g, 77%; (*Z*)-**1h**, 0.17 g, 90%; (*Z*)-**1k**, 0.24 g, 87%; (*Z*)-**1l**, 0.21 g, 83%; (*Z*)-**1n**, 0.19 g; 84%; (*Z*)-**1o**, 0.19 g, 90%; (*Z*)-**1p**, 0.24 g, 85%; (*Z*)-**1s**, 0.20 g, 87%), (Caldentey, *et al.* 2011).

## **3.2.7.** Synthesis of (*Z*)-1e and (*Z*)-1r



A mixture of (*Z*)-1d (194, mg, 1 mmol) or (*Z*)-1q (227 mg, 1.17 mmol), Et<sub>3</sub>N (0.18 mL, 1.3 mmol), *t*-butyldimethylsilyl chloride (0.2 g, 1.3 mmol), and 4-dimethylaminopyridine (DMAP) (15 mg, 0.12 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (12 mL) was stirred at RT for 24 h. Then, the reaction was terminated by water and the content of the reaction flask was extracted with DCM. The organic solution was dried with MgSO<sub>4</sub>, filtered, and evaporated. The residue was chromatographed over NEt<sub>3</sub>-pretreated short silica gel column to afford silylated enyne oxiranes as a colorless oil (hexane-EtOAc, yields: (*Z*)-1e, 0.28 g, 79%; (*Z*)-1r, 0.25 g, 81%), (Schmidt, *et al.* 2002).

# 3.2.8. Synthesis of (Z)-1f and (Z)-1g



To the dry Et<sub>2</sub>O (15 mL) solution of **S7** (1.1 g, 5 mmol) was added an ethereal (15 mL) solution of 2.1 eq. MeMgI (5.25 mL, 10.5 mmol, 2 M) dropwise at -50 °C, and then the mixture stirred for 6 h at the same temperature. The mixture was allowed to warm to 0 °C and quenched by the addition of 30 mL of saturated NH<sub>4</sub>Cl(*aq*) solution before extracting with Et<sub>2</sub>O. The combined extracts were dried over MgSO<sub>4</sub>, filtered, and evaporated. The resulting residue was purified on a silica gel column to afford **S25** (hexane-EtOAc, yield: 0.49 g, 80%).

The epoxidation of **S25** (412 mg, 2 mmol), and isolation of the product (*Z*)-**1f** was performed as specified for (*Z*)-**1i** (hexane-EtOAc, yield: 0.27 g, 60%).

The hydroxyl group of (*Z*)-**1f** (222 mg, 1.0 mmol) was methylated as described above furnishing the enyne oxirane (*Z*)-**1g** in 90% yield (0.21 g).

# **3.2.9.** Synthesis of (*E*)-1b

Synthesis of (*E*)-**1b** was performed starting from (*E*)-configured **S1** following the same method employed for the synthesis of (*Z*)-**1b**. Yields: ( $R^1$ = Bu,  $R^2$ = Me): (*E*)-**S7**, 1.12 g, 79%; (*E*)-**1d**, 0.83 g, 91%; (produced from 4.6 mmol of (*E*)-**S8**), 0.43 g, 47%; (*E*)-**1b** (produced from 2.2 mmol of (*E*)-**1d**), 0.40 g, 88%.

## **3.2.10.** Synthesis of (*Z*)-1t



PBr<sub>3</sub> (1.4 mL, 13.8 mmol) was added dropwise to a mixture of DMF (1.2 mL, 15.3 mmol) and chloroform (10 mL) at 0 °C and then the resulting mixture was stirred for 1 h. Subsequently, 0.5 g of cyclohexanone (6 mmol) was added dropwise and stirred for 8 h at RT. The reaction was terminated with water, neutralized with the addition of solid NaHCO<sub>3</sub>, and extracted with DCM. The extract was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The purification on short silica gel column provided the compound **S26** (hexane-EtOAc, 0.92 g, 81%), (Lian, *et al.* 2006).

A mixture of **S26** (945 mg, 5 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (123 mg, 0.1 mmol, 2 mol % of Pd), and CuI (21 mg, 0.1 mmol, 2 mmol % of Cu) in 10 mL of Et<sub>3</sub>N was stirred for 10 min at RT followed by the addition of 1-hexyne (0.5 g, 6 mmol). After being stirred for 3 h at RT, water was added and extracted with Et<sub>2</sub>O. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to obtain endocyclic enyne aldehyde **S27** (hexane-EtOAc, 0.84 g, 90%), (Lian, *et al.* 2006).

The conversion of **S27** (840 mg, 4.42 mmol) to dienyne ester **S28** was performed by HWE reaction as described above (hexane-EtOAc, 0.96 g, 84%). Further successive synthetic procedures; which involved the reduction of the ester **S28** (960 mg, 3.7 mmol) to the enyne alcohol **S29** (730 mg, 91% yield), the epoxidation of **S29** (436 mg, 2 mmol) to **S30** (260 mg, 55% yield), and finally methyl derivatization of hydroxyl group of **S30** (260 mg, 1.1 mmol) to obtain (*Z*)-**1r** (0.22 g, 90%) were all conducted as described above.

#### Me Me Me Ph<sub>2</sub>P(O)Et, BuLi NaBH₄ Bu Rι ĊO₂Et -78 °C MeOH Bu Ph $\cap$ rt S18 Мe S31 S32 *m*-CPBA Me Me NaH, DMF 25% Na<sub>2</sub>CO<sub>3</sub>(aq) rt Bu DCM. 0 °C Bu **S**33 (Z)-1j Ŵе Ńе

**3.2.11.** Synthesis of (*Z*)-1j

To a stirred solution of diphenylethylphosphine oxide (4.6 g, 20 mmol) in dry THF (70 mL) was added BuLi (2.5 M in hexane, 8.8 mL, 22 mmol) dropwise at 0 °C and stirred for a further 30 min. The solution was cooled to -78 °C and then the dienyne ester **S18'** (3.88 g, 20 mmol) was added dropwise. The solution was allowed to warm to ambient temperature and subsequently stirred overnight. Saturated NH<sub>4</sub>Cl(*aq*) solution was added and subsequently its THF content was removed under reduced pressure. The aqueous residue was diluted with brine (20 mL) and extracted with DCM. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The product **S31** was purified by column chromatography on silica gel (hexane-EtOAc, yield: 1.9 g, 25%), (Buss, *et al.* 1985).

To a stirred solution of **S31** (1.9 g, 5 mmol) in ethanol (50 mL) was added NaBH<sub>4</sub> (189 mg, 5 mmol) in one portion and stirred for a further 8h at ambient temperature. The reaction afforded **S32** enriched in *threo* form. Saturated NH<sub>4</sub>Cl(*aq*) (15 mL) was added and subsequently its ethanol content was removed under reduced pressure. The aqueous mixture was diluted with brine (20 mL), extracted with DCM. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The product **S32** was isolated in pure *threo* form by column chromatography on silica gel (hexane-EtOAc, yield: 1.31 g, 69%), (Buss, *et al.* 1985).

To a stirred solution of **S32** (1.31 g, 3.45 mmol) in DMF (50 ml) was added NaH (60% dispersion in oil; 138 mg, 3.45 mmol) in one portion at ambient temperature and

stirred for a further 3 h. The reaction was quenched by the addition 25 mL of water and 15 mL of brine and subsequently extracted with Et<sub>2</sub>O. The combined extracts were washed with water, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The product **S33** was purified by column chromatography on silica gel (hexane, yield: 330 mg, 59%), (Buss, *et al.* 1985).

The epoxidation of **S33** (162 mg, 1 mmol) and isolation of the product (*Z*)-**1j** was performed as specified for (*Z*)-**1i** (Hexane-EtOAc, yield: 35.6 mg, 20%).

# 3.2.12. Carbamate derivatization of 2ba and crystal growth for X-ray analysis



The mixture of vinylallene ester (45.2 mg, 0.2 mmol), phenyl isocyanate (31 mg, 0.26 mmol), and dry pyridine (15.8 mg, 0.2 mmol) in 2 mL of toluene was stirred at RT for 5 days. The mixture was taken into Et<sub>2</sub>O and washed with brine, dried over MgSO<sub>4</sub>, and filtered. The solvent was removed in vacuum, and the crude residue was purified by column chromatography on silica gel (hexane-EtOAc; 5:1, yield: 0.62 g, 80%). The pure white solid material was dissolved in a boiled hexane and gradually cooled down to 30 °C all through overnight.

## **3.3.** Characterization of Reactants

NMR spectra were recorded on a 400 MHz spectrometer. Chemical shifts are reported in ppm downfield from Me<sub>4</sub>Si.



(Z)-1a: <sup>1</sup>H NMR (400 MHz , CDCl<sub>3</sub>)  $\delta$ : 5.38 (dq, *J*= 8.9, 1.5 Hz, 1H), 3.65 (d, *J*= 8.9 Hz, 1H), 2.34 (t, *J*= 6.8 Hz, 2H), 1.87 (s, 3H), 1.56-1.36 (m, 4H), 1.35 (s, 3H), 1.27 (s, 3H), 0.9 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 130.7, 125.5, 95.9, 79.1, 62.6, 60.5, 30.9, 24.9, 24.2, 22.1, 19.6, 19.3, 13.7.



(*Z*)-**1b:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 5.23 (dd, *J*= 8.9, 1.2 Hz, 1H), 3.74 (dd, *J*= 8.9, 2.4 Hz, 1H), 3.71 (dd, *J*= 11.6, 3.2 Hz, 1H), 3.40 (dd, *J*= 11.6, 5.7 Hz, 1H), 3.40 (s, 3H), 3.08 (ddd, *J*= 5.7, 3.2, 2.4 Hz, 1H), 2.35 (t, *J*= 7.2 Hz, 2H), 1.87 (d, *J*= 1.2 Hz, 3H), 1.55-1.40 (m, 4H), 0.92 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 131.5, 125.7, 95.9, 78.7, 72.5, 59.2, 58.3, 54.2, 30.7, 23.8, 21.9, 19.1, 13.6.



(*E*)-**1b:** (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 5.35 (dd, *J*= 9.0, 1.0 Hz, 1H), 3.67 (dd, *J*= 11.3, 3.0 Hz, 1H), 3.48 (dd, *J*= 9.0, 2.2 Hz, 1H), 3.44 (dd, *J*= 11.3, 5.1 Hz, 1H), 3.38 (s, 3H), 3.06 (ddd, *J*= 5.1, 3.0, 2.2 Hz, 1H), 2.28 (t, *J*= 6.8 Hz, 2H), 1.93 (d, *J*= 1.0 Hz, 3H), 1.54-1.37 (m, 4H), 0.90 (t, *J*= 7.6 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 131.3, 125.2, 90.3, 82.4, 80.0, 59.2, 58.6, 51.9, 30.7, 21.9, 18.9, 18.2, 13.6.



(Z)-1c: <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 7.24-7.22 (m, 2H), 7.14-7.10 (m, 2H), 7.05 (dt, *J*= 7.2, 1.6 Hz, 1H), 5.14 (dd, *J*= 8.9, 1.6 Hz, 1H), 4.35 (d, A of AB, *J*<sub>AB</sub>=12.1 Hz, 1H), 4.31 (d, B of AB, *J*<sub>AB</sub>=12.1 Hz, 1H), 4.01 (dd, *J*= 8.9, 2.2 Hz, 1H), 3.45 (dd, *J*= 11.4, 3.0 Hz, 1H), 3.25 (dd, *J*= 11.4, 5.5 Hz, 1H), 2.95 (ddd, *J*= 5.5, 3.0, 2.2 Hz, 1H), 2.06 (t, *J*= 6.8 Hz, 2H), 1.71 (d, *J*= 1.6 Hz, 3H), 1.29-1.16 (m, 4H), 0.7 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 138.5, 132.8, 128.2, 127.4, 127.3, 124.8, 95.5, 79.1, 72.8, 70.0, 58.2, 53.8, 30.6, 23.5, 21.8, 18.9, 13.3.



(Z)-1d: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 5.25 (dd, *J*= 9.0, 1.4 Hz, 1H), 3.96 (dd, *J*= 12.6, 2.3 Hz, 1H), 3.87 (dd, *J*= 9.0, 2.3 Hz, 1H), 3.68 (dd, *J*= 12.6, 4.1 Hz, 1H), 3.11-3.09 (m, 1H), 2.36 (t, *J*= 7.0 Hz, 2H), 1.88 (d, *J*= 1.4 Hz, 3H), 1.56-1.39 (m, 4H), 0.92 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 132.5, 124.8, 95.7, 79.1, 61.1, 59.5, 53.7, 30.6, 23.5, 21.8, 19.0, 13.3.



(Z)-**1e:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 5.22 (dd, *J*= 9.1, 1.5 Hz, 1H), 3.86 (dd, *J*= 12.1, 3.2 Hz, 1H), 3.76 (dd, *J*= 9.1, 2.4 Hz, 1H), 3.71 (dd, *J*= 12.1, 4.8 Hz, 1H), 3.00 (ddd, *J*= 4.8, 3.2, 2.4 Hz, 1H), 2.33 (t, *J*= 7.2 Hz, 2H), 1.86 (d, *J*= 1.5 Hz, 3H), 1.56-1.37 (m, 4H), 0.91 (t, *J*= 6.8 Hz, 3H), 0.89 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H). <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 131.9, 125.3, 95.7, 78.7, 63.0, 60.1, 54.3, 30.8, 25.8, 23.8, 22.0, 19.1, 18.3, 13.6, -5.3, -5.4.



(Z)-**1f:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 5.26 (dd, *J*= 8.8, 1.6 Hz, 1H), 3.89 (dd, *J*= 8.8, 2.3 Hz, 1H), 2.88 (d, *J*= 2.3 Hz, 1H), 2.36 (t, *J*= 7.0 Hz, 2H), 1.87 (d, *J*= 1.6 Hz, 3H), 1.78 (d, *J*= 0.8 Hz, 1H), 1.57-1.40 (m, 4H), 1.31 (s, 3H), 1.25 (s, 3H), 0.92 (t, *J*= 6.8 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 132.0, 125.1, 78.8, 73.8, 64.7, 53.3, 50.7, 30.7, 23.7, 22.2, 21.9, 21.0, 19.1, 13.5.



(Z)-1g: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 5.24 (dd, *J*= 8.9, 1.5 Hz, 1H), 3.69 (dd, *J*= 8.9, 2.3 Hz, 1H), 3.29 (s, 3H), 2.87 (d, *J*= 2.3 Hz, 1H), 2.36 (t, *J*= 6.7 Hz, 2H), 1.87 (d, *J*= 1.5 Hz, 3H), 1.56-1.39 (m, 4H), 1.18 (s, 3H), 1.15 (s, 3H), 0.92 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 132.2, 125.3, 95.8, 79.0, 74.0, 64.9, 53.4, 50.9, 30.9, 23.9, 22.4, 22.0, 21.1, 19.2, 13.7.



(*Z*)-**1h:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 5.75 (dtd, *J*= 10.8, 2.4, 0.8 Hz, 1H), 5.44 (dd, *J*= 10.8, 8.8 Hz, 1H), 3.80 (dd, *J*= 8.8, 2.2 Hz, 1H), 3.74 (dd, *J*= 11.2, 2.8 Hz, 1H), 3.44-3.38 (m, 1H), 3.41 (s, 3H), 3.11 (dt, *J*= 5.4, 2.6 Hz, 1H), 2.36 (td, *J*= 6.8, 2.3 Hz, 2H), 1.58-1.41 (m, 4H), 0.92 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 137.2, 115.4, 97.1, 72.3, 59.2, 58.2, 53.3, 50.4, 30.6, 21.9, 19.2, 13.5.



(*Z*)-**1i:** <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 5.32 (d, *J*= 8.7 Hz, 1H), 3.90 (dd, *J*= 8.7, 2.3 Hz, 1H), 2.71 (td, *J*= 5.5, 2.3 Hz, 1H), 2.11 (t, *J*= 6.8 Hz, 2H), 2.10 (t, *J*= 6.4 Hz, 2H), 1.54-1.15 (m, 14H), 0.84-0.70 (m, 9H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 137.5, 133.3, 95.7, 78.6, 59.6, 56.4, 37.4, 31.8, 30.7, 30.3, 28.0, 22.4, 22.0, 21.8, 19.0, 13.7, 13.6, 13.3.



(Z)-1i': <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 5.38 (d, J= 9.0, 1H), 3.90 (dd, J= 9.0, 4.8 Hz, 1H), 3.11 (q, J= 4.8 Hz, 1H), 2.37 (t, J= 6.8 Hz, 2H), 2.15 (td, J= 7.6, 0.8 Hz, 2H), 1.60-1.25 (m, 14H), 0.95-0.88 (m, 9H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 130.8, 128.9, 96.4, 78.1, 59.1, 55.4, 37.5, 30.8, 30.2, 28.5, 28.2, 22.5, 21.9, 21.9, 19.2, 14.0, 13.9, 13.8.



(Z)-**1**j: <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 5.16 (dd, *J*= 8.9, 1.4 Hz, 1H), 3.75 (dd, *J*= 8.9, 2.1 Hz, 1H), 2.64 (qd, *J*= 5.4, 2.1 Hz, 1H), 2.08 (t, *J*= 6.8 Hz, 2H), 1.73 (d, *J*= 1.4 Hz, 3H), 1.31-1.20 (m, 4H), 1.04 (d, *J*= 5.2 Hz, 3H), 0.72 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 133.7, 123.9, 95.2, 79.3, 57.4, 55.2, 30.6, 23.4, 21.8, 19.0, 17.3, 13.2.



(*Z*)-**1k:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.21 (d, *J*= 8.7 Hz, 1H), 3.77 (dd, *J*= 8.7, 2.4 Hz, 1H), 3.72 (dd, *J*= 11.5, 3.1 Hz, 1H), 3.38 (dd, *J*= 11.5, 5.7 Hz, 1H), 3.40 (s, 3H),

3.07 (dt, *J*= 5.7, 2.4 Hz, 1H), 2.37 (t, *J*= 7.2 Hz, 2H), 2.02-1.97 (m, 1H), 1.76-1.20 (m, 14H), 0.92 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>) δ: 136.3, 129.1, 97.0, 76.7, 72.6, 59.2, 58.5, 54.3, 45.4, 31.7, 31.6, 30.8, 29.7, 26.2, 26.0, 22.0, 19.2, 13,6.



(Z)-**11:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 5.24 (d, *J*= 8.9 Hz, 1H), 3.81 (dd, *J*= 8.9, 2.4 Hz, 1H), 3.74 (dd, *J*= 11.2, 3.1 Hz, 1H), 3.42-3.38 (m, 1H), 3.41 (s, 3H), 3.10 (ddd, *J*= 5.6, 3.1, 2.4 Hz, 1H), 2.39 (t, *J*= 7.2 Hz, 2H), 1.59-1.41 (m, 4H), 1.11 (s, 9H), 0.93 (t, *J*= 7.6 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 140.2, 127.4, 97.4, 72.7, 59.2, 58.5, 54.7, 36.1, 30.8, 28.9, 21.9, 19.2, 13.6.



(*Z*)-**1m:** <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 5.10 (dq, *J*= 8.9, 1.0 Hz, 1H), 3.84 (dd, *J*= 8.9, 2.0 Hz, 1H), 3.25 (dd, *J*= 11.5, 3.0 Hz, 1H), 3.06-2.99 (m, 1H), 3.05 (s, 3H), 2.83 (ddd, *J*= 5.5, 3.0, 2.0 Hz, 1H), 2.74 (s, 1H), 1.57 (d, *J*= 1.0 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 136.0, 122.9, 82.4, 81.5, 72.2, 58.4, 58.0, 53.2, 22.7.



(Z)-**1n:** <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 5.14 (dq, *J*= 9.0, 1.4 Hz, 1H), 4.01 (dd, *J*= 9.0, 2.0 Hz, 1H), 3.35 (dd, *J*= 11.3, 3.2 Hz, 1H), 3.16 (dd, *J*= 11.3, 5.5 Hz, 1H), 3.09 (s, 3H), 2.91 (ddd, *J*= 5.5, 3.2, 2.0 Hz, 1H), 2.34 (m, 1H), 1.71 (d, *J*= 1.4 Hz, 3H), 1.66-1.03 (m, 10H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 132.7, 124.7, 99.5, 79.2, 72.4, 58.5, 58.1, 53.7, 32.5, 32.4, 29.6, 25.7, 24.6, 23.5.



(*Z*)-**10:** <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 5.12 (dd, *J*= 8.5, 1.3 Hz, 1H), 3.95 (dd, *J*= 8.5, 2.3 Hz, 1H), 3.34 (dd, *J*= 11.5, 3.1 Hz, 1H), 3.16 (dd, *J*= 11.5, 5.5 Hz, 1H), 3.09 (s, 3H), 2.90 (ddd, *J*= 5.5, 3.1, 2.3 Hz, 1H), 1.68 (d, *J*= 1.3 Hz, 3H), 1.12 (s, 9H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 132.8, 124.5, 103.4, 77.7, 72.4, 58.5, 58.0, 53.7, 30.6, 27.9, 23.4.



(*Z*)-**1p:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.35-7.28 (m, 5H), 5.22 (dq, *J*= 8.9, 1.4 Hz, 1H), 4.61 (d, A of AB, *J*<sub>AB</sub>=12.0 Hz, 1H), 4.57 (d, B of AB, *J*<sub>AB</sub>=12.0 Hz, 1H), 3.81 (dd, *J*= 11.3, 3.0 Hz, 1H), 3.76 (dd, *J*= 8.9, 2.2 Hz, 1H), 3.53 (dd, *J*= 11.3, 5.5 Hz, 1H), 3.13 (ddd, *J*= 5.5, 3.0, 2.2 Hz, 1H), 1.86 (d, *J*= 1.4 Hz, 3H), 1.24 (s, 9H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 140.0, 137.9, 131.3, 128.4, 127.7, 125.7, 104.0, 77.1, 73.3, 70.1, 58.6, 54.3, 31.0, 28.1, 23.8.



(Z)-1q: <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 5.17 (dd, *J*= 8.9, 1.1 Hz, 1H), 4.1 (dd, *J*= 8.9, 2.3 Hz, 1H), 3.54-3.48 (m, 1H), 3.34-3.30 (m, 1H), 2.75-2.73 (m, 1H), 1.73 (d, *J*= 1.1 Hz, 3H), 1.17 (s, 9H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 132.5, 124.6, 103.7, 77.6, 61.0, 59.4, 53.6, 30.6, 27.9, 23.4.



(Z)-1r: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.21 (d, J= 9.0 Hz, 1H), 3.87 (dd, J= 12.0, 3.2 Hz, 1H), 3.74 (m, 2H), 3.01 (m, 1H), 1.86 (s, 3H), 1.26 (s, 9H), 0.90 (s, 9H), 0.08 (s, 6H); <sup>13</sup>C{1H} NMR: (100 MHz, CDCl<sub>3</sub>) δ: 131.6, 125.3, 103.8, 77.1, 62.9, 60.2, 54.3, 31.0, 28.1, 25.9, 23.9, 18.3, -5,3.



(Z)-1s: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.46-7.44 (m, 2H), 7.34-7.32 (m, 3H), 5.38 (dq, *J*= 9.0, 1.5 Hz, 1H), 3.84 (dd, *J*= 9.0, 2.4 Hz, 1H), 3.74 (dd, *J*= 11.7, 3.2 Hz, 1H), 3.43 (dd, *J*= 11.7, 6.0 Hz, 1H), 3.42 (s, 3H) 3.14 (ddd, *J*= 6.0, 3.2, 2.4 Hz, 1H), 2.00 (d, *J*= 1.5 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 133.1, 131.5, 128.5, 128.3, 124.9,122.9, 94.5, 87.3, 72.5, 59.2, 58.5, 54.1, 23.4.



(Z)-**1t:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 4.00-3.97 (m, 1H), 3.73 (dt, *J*= 11.2, 2.8 Hz, 1H), 3.45-3.30 (m, 4H), 3.20 (sext, *J*= 2.8 Hz, 1H), 2.34 (t, *J*= 6.8 Hz, 2H), 2.21-2.10 (m, 2H), 2.02-1.91 (m, 2H), 1.79-1.32 (m, 6H), 0.98-0.79 (m, 5H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 137.3, 121.7, 94.2, 79.5, 73.1, 59.2, 56.2, 55.2, 30.9, 30.8, 22.4, 22.2, 21.9, 21.7, 19.2, 13.6.



**S31:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.86-7.74 (m, 4H), 7.55-7.43 (m, 6H), 6.34 (d, *J*= 1.2 Hz, 1H), 3.99 (dq, *J*= 13.5, 7.0 Hz, 1H), 2.42 (t, *J*= 7.0 Hz, 2H), 1.89 (d, *J*= 1.2 Hz, 3H), 1.60-1.51 (m, 2H), 1.47-1.38 (m, 5H), 0.92 (t, *J*= 7.0 Hz, 3H).



**S32:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.83-7.71 (m, 4H), 7.56-7.43 (m, 6H), 5.53 (dd, *J*= 8.3, 1.2 Hz, 1H), 4.80 (dt, *J*= 13.8, 8.3 Hz, 1H), 2.82-2.71 (m, 1H), 2.15 (t, *J*= 7.2 Hz, 2H), 1.65 (d, *J*= 1.2 Hz, 3H), 1.40-1.28 (m, 4H), 1.04 (dd, *J*= 17.2, 7.4 Hz, 3H), 0.78 (t, *J*= 7.2 Hz, 3H).



**S33:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.48 (ddq, *J*= 15.4, 10.8, 1.6 Hz, 1H), 6.11 (d, *J*= 10.8 Hz, 1H), 4.80 (dq, *J*= 15.4, 7.0 Hz, 1H), 2.39 (t, *J*= 6.8 Hz, 2H), 1.86 (s, 3H), 1.79 (d, *J*= 7.0 Hz, 3H), 1.60-1.52 (m, 2H), 1.51-1.44 (m, 2H), 0.94 (t, *J*= 6.8 Hz, 3H).

## **3.4. General Procedure for Carbonylation Reactions**

A palladium complex, phosphine ligand and 1 mL of alcohol were added successively to a Schlenck apparatus that is attached to an Ar line and stirred 1 h at 25 °C before the addition of the substrate. A CO full balloon was then fixed to the reaction vessel and 1 mL alcohol solution of the substrate was added. When the reaction was complete as judged by TLC analysis the solvent content was evaporated and the residue was purified by column chromatography on silica gel to afford **2** as a pale yellow oil.

## **3.5.** Characterization of Products

The synthesized carbonylation products were analyzed by GC and GC-MS. NMR spectra were recorded on a 400 MHz spectrometer. Chemical shifts are reported in ppm downfield from Me<sub>4</sub>Si. Infrared spectra were obtained by ATR method with neat samples. High-resolution mass spectral analyses of new compounds were performed using EI-High Resolution Double Focusing Magnetic Sector (ionization mode: 70 eV, emission current: 1 mA, source temperature: 160 °C, resolution: 10,000 (10% valley definition)) and ESI-LTQ Orbitrap (source voltage: +3.8 kV, capillary voltage: 41 V, capillary temperature: 275 °C, tube lens voltage: 140 V, system resolution: 60,000 (10% valley definition)). The coupling constants of olefinic protons and NOE studies confirmed (*E*)-configured structures. <sup>1</sup>H NMR analyses of vinylallene products, except that of **2ia'**, were performed in C<sub>6</sub>D<sub>6</sub>. With this solvent, the <sup>1</sup>H NMR signals of diastereomers were resolved adequately, allowing to determine diastereomeric ratios smoothly. In contrast, when using CDCl<sub>3</sub> solvent, diastereomeric signals were all overlapped.



**2aa:** Yield: 24.9 mg (99%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 6.13 (d, *J*= 16.0 Hz, 1H), 5.76 (d, *J*= 16.0 Hz, 1H), 3.67 (s, 3H), 2.22 (t, *J*= 7.6 Hz, 2H), 1.85 (s, 3H), 1.37-1.27 (m, 10H), 0.86 (t, *J*= 7.0 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.4, 167.7, 137.8, 122.9, 103.1, 99.7, 70.9, 52.0, 30.1, 29.8, 28.6, 22.1, 14.8, 13.8; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3409, 2957, 2930, 2871, 1940, 1714, 1436, 1378, 1264, 1133, 1083, 1019, 966, 912, 723, 696; MS (EI, m/z): 252 (1, M<sup>+</sup>), 234 (2), 205 (7), 194 (7), 179 (5), 151 (23), 135 (35), 121 (15), 107 (32), 91 (43), 77 (25), 65 (15), 59 (46), 43 (100); HRMS (ESI) C<sub>15</sub>H<sub>25</sub>O<sub>3</sub> (MH)<sup>+</sup>, 253.1798 (calculated); 253.1799 (found).



**2ba:** Yield: 25.2 mg (94%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.43 (dd, *J*= 15.7, 1.6 Hz, 1H, major), 6.41 (dd, *J*= 15.7, 1.6 Hz, 1H, minor), 5.51 (dd, *J*= 15.7, 5.5 Hz, 1H, major), 5.51 (dd, *J*= 15.7, 5.5 Hz, 1H, minor), 4.23-4.19 (m, 1H), 3.36 (s, 3H, major), 3.35 (s, 3H, minor), 3.03 (dd, A of ABX, *J*<sub>AB</sub>=9.2 Hz, *J*<sub>AX</sub>=4.0 Hz, 1H), 2.98 (dd, B of ABX, *J*<sub>AB</sub>=9.2 Hz, *J*<sub>BX</sub>=7.2 Hz, 1H), 2.95 (s, 3H), 2.39 (td, *J*= 7.5, 2.2 Hz, 2H), 2.23 (bs, 1H), 1.69 (s, 3H), 1.47-1.39 (m, 2H), 1.23 (sext, *J*= 7.6 Hz, 2H), 0.78 (t, *J*= 7.2 Hz, 3H, major), 0.78 (t, *J*= 7.2 Hz, 3H, minor); <sup>13</sup>C{1H} NMR: (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 213.5, 166.9, 129.2, 127.3, 103.1, 76.5, 70.6, 58.2, 51.3, 30.3, 28.9, 22.2, 14.5, 13.7; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3419, 2955, 2928, 2870, 1943, 1715, 1456, 1436, 1379, 1266, 1241, 1193, 1129, 1016, 966; MS (EI, m/z): 268 (1, M<sup>+</sup>), 236 (1), 223 (4), 205 (1), 191 (6), 151 (2), 135 (7), 121 (6), 93 (8), 91 (14), 77 (10), 59 (6), 45 (100); HRMS (ESI): C<sub>15</sub>H<sub>25</sub>O<sub>4</sub> (MH)<sup>+</sup>, 269.1747 (calculated); 269.1747 (found).



**2ba':** Yield: 23.3 mg, (87%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.42 (dd, *J*= 15.7, 1.6 Hz, 1H, major), 6.40 (dd, *J*= 15.7, 1.6 Hz, 1H, minor), 5.52 (dd, *J*= 15.7, 5.7 Hz, 1H), 4.22-4.20 (m, 1H), 3.37 (s, 3H, major), 3.35 (s, 3H, minor), 3.03 (dd, A of ABX, *J*<sub>AB</sub>=9.6 Hz, *J*<sub>AX</sub>=4.0 Hz, 1H), 2.99 (dd, B of ABX, *J*<sub>AB</sub>=9.6 Hz, *J*<sub>BX</sub>=8.0 Hz, 1H), 2.96 (s, 3H), 2.38 (td, *J*= 7.6 Hz, 1.8 Hz, 2H), 2.29 (bs, 1H), 1.70 (s, 3H), 1.48-1.40 (m, 2H), 1.25 (sext, *J*= 7.6 Hz, 2H), 0.79 (t, *J*= 7.6 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 213.5, 166.9, 129.2, 103.1, 100.0, 76.5, 70.6, 58.2, 51.3, 30.3, 28.9, 22.2, 14.5, 13.7; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3419, 2955, 2928, 2870, 1943, 1715, 1456, 1436, 1379, 1266, 1241, 1193, 1129, 1016, 966; MS (EI, m/z): 268 (1, M<sup>+</sup>), 236 (1), 223 (4), 205 (1), 191 (6), 151 (2), 135 (7), 121 (6), 93 (8), 91 (14), 77 (10), 59 (6), 45 (100); HRMS (ESI): C<sub>15</sub>H<sub>25</sub>O<sub>4</sub> (MH)<sup>+</sup>, 269.1747 (calculated); 269.1747 (found).



**2bb:** Yield: 23.7 mg (84%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.44 (dd, *J*= 15.4, 1.6 Hz, 1H, major), 6.43 (dd, *J*= 15.4, 1.6 Hz, 1H, minor), 5.54 (dd, *J*= 15.4, 5.6 Hz, 1H), 4.24-4.18 (m, 1H), 3.99 (q, *J*=7.1 Hz, 2H), 3.03 (dd, A of ABX, *J*<sub>AB</sub>=9.6 Hz, *J*<sub>AX</sub>=4.0 Hz, 1H), 2.98 (dd, B of ABX, *J*<sub>AB</sub>=9.6 Hz, *J*<sub>BX</sub>=7.6 Hz, 1H), 2.95 (s, 3H), 2.41 (td, *J*= 7.2, 2.4 Hz, 2H) 2.28 (bs, 1H), 1.71 (s, 3H), 1.49-1.41 (m, 2H), 1.25 (sext, *J*=7.2 Hz, 2H), 0.92 (t, *J*= 7.1 Hz, 3H, major), 0.91 (t, *J*= 7.1 Hz, 3H, minor) 0.79 (t, *J*= 7.2 Hz, 3H, major), 0.79 (t, *J*= 7.2 Hz, 3H, minor); <sup>13</sup>C{1H} NMR: (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.5, 167.1, 128.7, 127.8, 103.1, 100.3, 76.4, 71.1, 60.8, 59.1, 30.2, 28.6, 22.2, 14.7, 14.3, 13.9; FTIR ( $v_{max}/cm^{-1}$ ): 3418, 2956, 2926, 2858, 1940, 1708, 1458, 1367, 1322, 1261, 1240, 1172, 1118, 1062, 1023, 965, 864, 713. MS (EI, m/z) : 282 (1, M<sup>+</sup>), 238 (1), 237 (4), 209 (2), 191 (5), 135 (3), 121 (5), 107 (6), 93 (8), 91 (12), 77 (7), 65 (5), 55 (7), 45 (100); HRMS (ESI): C<sub>16</sub>H<sub>26</sub>O<sub>4</sub> (MH)<sup>+</sup>, 283.1904 (calculated); 283.1909 (found).



**2bc:** Yield: 25.8 mg (87%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.44 (dd, *J*= 15.8, 1.6 Hz, 1H, major), 6.43 (dd, *J*= 15.8, 1.6 Hz, 1H, minor), 5.53 (dd, *J*= 15.8, 5.6 Hz, 1H), 4.23-4.19 (m, 1H), 4.02-3.92 (m, 2H), 3.03 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.4 Hz, 1H), 2.98 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.94 (s, 3H), 2.41 (td, *J*= 7.3, 1.6 Hz, 2H), 2.22 (bs, 1H), 1.72 (s, 3H), 1.49-1.33 (m, 4H), 1.25 (sext, *J*= 7.4 Hz, 2H), 0.79 (t, *J*= 7.4 Hz, 3H, major), 0.80 (t, *J*= 7.4 Hz, 3H, minor), 0.66 (t, *J*= 7.3 Hz, 3H, major), 0.65 (t, *J*= 7.3 Hz, 3H, minor); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.6, 167.2, 128.6, 127.9, 103.1, 100.3, 76.5, 71.1, 66.3, 59.1, 30.2, 28.5, 22.2, 22.0, 14.7, 13.9, 10.3; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3406, 2958, 2928, 1941, 1709, 1458, 1397, 1322, 1263, 1172, 1132, 1062, 1015, 965, 713; MS (EI, m/z): 296 (1, M<sup>+</sup>), 278 (1), 251 (3), 236 (1), 209 (3), 191

(5), 135 (4), 121 (5), 91 (10), 79 (6), 65 (3), 45 (100); HRMS (ESI):  $C_{17}H_{28}O_4$  (MH)<sup>+</sup>, 297.2060 (calculated), 297.2065 (found).



**2bd:** Yield: 25.7 mg (83%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.45 (dd, *J*= 16.0, 1.2 Hz, 1H, major), 6.43 (dd, *J*= 16.0, 1.2 Hz, 1H, minor), 5.53 (dd, *J*= 16.0, 5.6 Hz, 1H, major), 5.53 (dd, *J*= 16, 5.6 Hz, 1H, minor), 4.24-4.19 (m, 1H), 4.09-3.99 (m, 2H), 3.04 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 2.99 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.6 Hz, 1H), 2.95 (s, 3H), 2.41 (td, *J*= 7.4, 2.4 Hz, 2H) 2.26 (bs, 1H), 1.75 (s, 3H, minor), 1.73 (s, 3H, major), 1.46 (quint, *J*= 7.2 Hz, 2H), 1.36 (quint, *J*= 7.4 Hz, 2H), 1.25 (sext, *J*= 7.2 Hz, 2H), 1.12 (sext, *J*= 7.4 Hz, 2H), 0.80 (t, *J*= 7.2 Hz, 3H, minor), 0.79 (t, *J*= 7.2 Hz, 3H, major), 0.68 (t, *J*= 7.4 Hz, 3H, major), 0.67 (t, *J*= 7.4 Hz, 3H, minor); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.6, 167.2, 128.6, 127.8, 103.1, 100.3, 76.4, 71.1, 64.7, 59.1, 30.6, 30.2, 28.5, 22.2, 19.2, 14.7, 13.9, 13.7; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3428, 2958, 2929, 2873, 1940, 1710, 1458, 1379, 1322, 1261, 1131, 1062, 1016, 965, 713; MS (EI, m/z): 310 (1, M<sup>+</sup>), 293 (1), 265 (1), 235 (2), 207 (4), 191 (4), 161 (3), 121 (3), 105 (5), 91 (10), 79 (5), 57 (15), 45 (100); HRMS (ESI): C<sub>18</sub>H<sub>31</sub>O<sub>4</sub> (MH)<sup>+</sup>, 311.2217 (calculated), 311.2219 (found).



**2be:** Yield: 26.1 mg (88%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.43 (dd, *J*= 16.0, 1.6 Hz, 1H), 5.51 (dd, *J*= 16.0, 5.6 Hz, 1H), 5.05 (sept, *J*= 6.4 Hz, 1H, major), 5.05 (sept, *J*= 6.4 Hz, 1H, minor), 4.23-4.16 (m, 1H), 3.02 (dd, A of ABX, *J*<sub>AB</sub>= 9.2 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 2.97 (dd, B of ABX, *J*<sub>AB</sub>= 9.2 Hz, *J*<sub>BX</sub>= 7.6 Hz, 1H), 2.94 (s, 3H), 2.42 (td, *J*= 7.6, 2.0 Hz, 2H), 2.21 (bs, 1H), 1.71 (s, 3H), 1.45 (quint, *J*= 7.6 Hz, 2H), 1.25 (sext, *J*= 7.6 Hz, 2H), 1.02 (d, *J*= 6.4 Hz, 3H), 1.01 (d, *J*= 6.4 Hz, 3H), 0.79 (t, *J*= 7.6 Hz, 3H, major),

0.79 (t, J= 7.6 Hz, 3H, minor); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.5, 166.7, 128.9, 127.6, 103.0, 100.7, 76.5, 71.1, 68.1, 59.1, 30.2, 28.6, 22.2, 21.9, 21.8, 14.7, 13.9; FTIR ( $\nu_{max}/cm^{-1}$ )  $\delta$ : 3442, 2957, 2927, 1942, 1706, 1457, 1373, 1322, 1264, 1107, 1062, 1014, 966,831,713; MS (EI, m/z): 296 (1, M<sup>+</sup>), 282 (1), 251 (2), 209 (3), 191 (4), 180 (1), 121 (6), 107 (4), 91 (7), 77 (6), 55 (4), 45 (100); HRMS (ESI): C<sub>17</sub>H<sub>29</sub>O<sub>4</sub> (MH)<sup>+</sup>, 297.2060 (calculated), 297.2060 (found).



**2bg:** Yield: 26.8 mg (91%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.43 (dd, *J*= 15.6, 0.8 Hz, 1H), 5.72-5.62 (m, 1H), 5.52 (dd, *J*= 15.6, 5.6 Hz, 1H), 5.08 (dq, *J*= 18.8, 1.6 Hz, 1H), 4.89 (dq, *J*= 6.4, 1.6 Hz, 1H), 4.53-4.41 (m, 2H), 4.23-4.19 (m, 1H), 3.04 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 2.99 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.95 (s, 3H), 2.39 (td, *J*= 7.2, 2.0 Hz, 2H), 2.31 (bs, 1H), 1.70 (s, 3H), 1.44 (quint, *J*= 7.2 Hz, 2H), 1.24 (sext, *J*= 7.2 Hz, 2H), 0.79 (t, *J*= 7.2 Hz, 3H, minor), 0.78 (t, *J*= 7.2 Hz, 3H, major); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.7, 166.8, 132.4, 128.5, 128.1, 117.4, 103.2, 100.0, 76.4, 71.1, 65.2, 59.1, 30.1, 28.5, 22.2, 14.7, 13.9; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3417, 2956, 2928, 2873, 1939, 1710, 1647, 1456, 1379, 1322, 1259, 1236, 1172, 1129, 1062, 1015, 965, 928, 837, 713. MS (EI, m/z): 294 (1, M<sup>+</sup>), 261 (1), 249 (2), 221 (1), 191 (5), 165 (3), 121 (6), 91 (11), 77 (9), 65 (4), 55 (7), 45 (100); HRMS (ESI): C<sub>17</sub>H<sub>27</sub>O<sub>4</sub> (MH)<sup>+</sup>, 295.1904 (calculated), 295.1910 (found).



**2ca:** Yield: 31.0 mg (90%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 7.24-7.01 (m, 5H), 6.44 (dd, *J*= 15.8, 1.6 Hz, 1H, major), 6.42 (dd, *J*= 15.8, 1.6 Hz, 1H, minor), 5.49 (dd, *J*= 15.8, 5.7 Hz, 1H), 4.29-4.23 (m, 1H), 4.21 (d, A of AB, *J*<sub>AB</sub>=12.0 Hz, 1H), 4.19 (d, B of AB, *J*<sub>AB</sub>=12.0 Hz, 1H), 3.36 (s, 3H, major) 3.34 (s, 3H, minor), 3.18 (dd, A of ABX, *J*<sub>AB</sub>= 9.2

Hz,  $J_{AX}$ = 3.6 Hz, 1H), 3.11 (dd, B of ABX,  $J_{AB}$ = 9.2 Hz,  $J_{BX}$ = 7.6 Hz, 1H), 2.38 (td, J= 7.6, 2.8 Hz, 2H), 1.69 (s, 3H), 1.42 (quint, J= 7.6 Hz, 2H), 1.23 (sext, J=7.6 Hz, 2H), 0.78 (t, J= 7.6 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.6, 167.6, 137.7, 128.5, 128.4, 128.0, 127.9, 127.8, 103.2, 99.9, 74.0, 73.4, 71.2, 52.1, 30.1, 28.6, 22.2, 14.7, 13.9; FTIR ( $v_{max}$ /cm<sup>-1</sup>): 3416, 2954, 2928, 2869, 1943, 1714, 1454, 1435, 1379, 1322, 1266, 1134, 1016, 965, 738, 698. MS (EI, m/z): 344 (1, M<sup>+</sup>), 312 (1), 279 (3), 253 (2), 191 (2), 167 (20), 149 (77), 113 (10), 104 (12), 91 (65), 70 (35), 57 (42), 57 (54), 43 (80), 41 (100); HRMS (ESI): C<sub>21</sub>H<sub>29</sub>O<sub>4</sub> (MH)<sup>+</sup>, 345.2060 (calculated); 345.2065 (found).



**2da:** Yield: 21.3 mg (84%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ : 6.35 (d, *J*= 16.0 Hz, 1H, major), 6.34 (d, *J*= 16.0 Hz, 1H, minor), 5.48 (dd, *J*= 16.0, 5.9 Hz, 1H), 4.10-4.04 (m, 1H), 3.44-3.24 (m, 2H), 3.37 (s, 3H), 2.39 (td, *J*= 7.6, 3.2 Hz, 2H), 1.70 (s, 3H), 1.44 (quint, *J*= 7.6 Hz, 2H), 1.25 (sext, *J*=7.6 Hz, 2H), 0.80 (t, *J*= 7.6 Hz, 3H, major), 0.80 (t, *J*= 7.2 Hz, 3H, minor); <sup>13</sup>C{1H} NMR: (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 213.6, 167.0, 129.2, 128.0, 103.2, 100.1, 72.8, 66.3, 51.4, 30.3, 28.9, 22.2, 14.5, 13.7; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3384, 2954, 2928, 2871, 1940, 1715, 1436, 1379, 1265, 1240, 1131, 1076, 1017, 965, 875; LC-MS/MS: 255 (100, MH<sup>+</sup>), 237 (20), 227 (8), 225 (20), 223 (42), 207 (12), 205 (50), 195 (12), 193 (15), 177 (18), 175 (18), 163 (15), 149 (8); HRMS (ESI): C<sub>14</sub>H<sub>23</sub>O<sub>4</sub> (MH)<sup>+</sup>, 255.1596 (calculated); 255.1591 (found).



**2ea:** Yield: 30.2 mg (82%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.45 (dd, *J*= 15.8, 1.6 Hz, 1H, major), 6.34 (dd, *J*= 15.8, 1.6 Hz, 1H, minor) 5.54 (dd, *J*= 15.8, 5.6 Hz, 1H, major), 5.50 (dd, *J*= 15.8, 5.6 Hz, 1H, minor), 4.19-4.10 (m, 1H), 3.42 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.4 Hz, 1H), 3.37 (s, 3H), 3.31 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.39 (td, *J*= 7.2, 1.6 Hz, 2H), 2.24 (d, *J*= 3.6 Hz, 1H), 1.72 (s, 3H, major), 1.69 (s, 3H, minor), 1.44 (quint, *J*= 7.2 Hz, 2H), 1.24 (sext, *J*=7.2 Hz, 2H), 0.89 (s, 9H, minor),

0.85 (s, 9H, major), 0.79 (t, J= 7.2 Hz, 3H), -0.06 (s, 6H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 213.5, 166.9, 129.2, 127.5, 103.1, 100.0, 72.4, 67.2, 51.3, 30.3, 28.9, 25.6, 22.2, 18.1, 14.5, 13.7, -5.6, -5.7; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3465, 2954, 2928, 2858, 1940, 1716, 1463, 1435, 1361, 1258, 1118, 963, 837, 777; MS (EI, m/z): 368 (1, M<sup>+</sup>), 339 (1), 311 (2), 279 (1), 249 (3), 219 (2), 191 (4), 175 (5), 159 (6), 145 (3), 121 (5), 117 (15), 105 (30), 91 (20), 77 (20), 75 (100), 73 (50), 57 (85), 41 (60); HRMS (ESI): C<sub>20</sub>H<sub>37</sub>O<sub>4</sub>Si (MH)<sup>+</sup>, 369.2456 (calculated), 369.2470 (found).



**2fa:** Yield: 25.4 mg (90%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.29 (dd, *J*= 15.7, 1.2 Hz, 1H, minor), 6.28 (dd, *J*= 15.7, 1.2 Hz, 1H, major), 5.63 (dd, *J*= 15.7, 6.6 Hz, 1H, minor), 5.62 (dd, *J*= 15.7, 6.6 Hz, 1H, major), 3.73 (d, *J*= 6.6 Hz, 1H), 3.36 (s, 3H, major), 3.34 (s, 3H, minor), 2.38 (td, *J*= 7.2, 1.6 Hz, 2H), 2.15 (bs, 1H), 2.00 (bs, 1H), 1.71 (s, 3H, minor), 1.71 (s, 3H, major), 1.43 (quint, *J*= 7.2 Hz, 2H), 1.23 (sext, *J*= 7.2 Hz, 2H), 1.06 (s, 3H, major), 1.05 (s, 3H, minor), 1.03 (s, 3H, minor), 1.02 (s, 3H, major), 0.78 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 213.5, 166.9, 129.3, 128.4, 103.2, 100.0, 79.2, 72.3, 51.3, 30.3, 28.8, 26.1, 23.8, 22.1, 14.5, 13.6; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3407, 2956, 2929, 2860, 1940, 1714, 1436, 1377, 1265, 1242, 1133, 1015, 965, 898; MS (EI, m/z): 282 (2, M<sup>+</sup>), 250 (2), 222 (1), 191 (3), 164 (4), 134 (4), 121 (20), 91 (7), 77 (16), 65 (5), 59 (100), 43 (37); HRMS (ESI): C<sub>16</sub>H<sub>27</sub>O<sub>4</sub> (MH)<sup>+</sup>: 283.1904 (calculated), 283.1908 (found).



**2ga:** Yield: 26.3 mg (89%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.45 (dd, *J*= 15.8, 1.6 Hz, 1H), 5.68 (dd, *J*= 15.8, 6.2 Hz, 1H), 3.96 (d, *J*= 6.2 Hz, 1H), 3.36 (s, 3H, major), 3.33 (s, 3H, minor), 2.86 (s, 3H), 2.44 (bs, 1H), 2.38 (td, *J*= 7.6, 1.6 Hz, 2H), 1.72 (s, 3H), 1.43 (quint, *J*= 7.6 Hz, 2H), 1.23 (sext, *J*= 7.6 Hz, 2H), 0.93 (s, 3H), 0.88 (s, 3H), 0.78 (t, *J*= 7.6 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 213.4, 166.9, 129.1, 103.2, 99.9, 77.6,

77.1, 51.3, 48.6, 30.3, 28.9, 22.1, 20.2, 19.2, 14.6, 13.7; FTIR ( $v_{max}/cm^{-1}$ ): 3446, 2953, 2928, 2859, 1939, 1712, 1459, 1435, 1380, 1321, 1264, 1241, 1118, 1062, 1015, 965, 861, 833, 740, 713; MS (EI, m/z): 296 (1, M<sup>+</sup>), 265 (1), 233 (1), 221 (1), 191 (1), 121 (3), 91 (5), 74 (4), 73 (100), 59 (5), 43 (20); HRMS (ESI): C<sub>17</sub>H<sub>29</sub>O<sub>4</sub> (MH)<sup>+</sup>: 297.2060 (calculated), 297.2063 (found).



**2ha:** Yield: 22.1 mg (87%): <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.24 (ddd, *J*= 15.2, 10.6, 1.6 Hz, 1H), 5.98 (dt, *J*= 10.6, 2.7 Hz, 1H), 5.46 (ddd, *J*= 15.2, 4.8, 0.8 Hz, 1H), 4.16-4.08 (m, 1H), 3.36 (s, 3H, major), 3.35 (s, 3H, minor), 2.99 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 2.93 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.6 Hz, 1H), 2.93 (s, 3H), 2.41-2.29 (m, 2H), 2.20 (bs, 1H), 1.42 (quint, *J*= 7.2 Hz, 2H), 1.23 (sext, *J*= 7.2 Hz, 2H), 0.79 (t, *J*= 7.2 Hz, 3H, minor), 0.78 (t, *J*= 7.2 Hz, 3H, major); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 213.8, 166.6, 132.7, 124.1, 101.9, 97.0, 76.3, 70.3, 58.2, 51.3, 30.2, 28.6, 22.1, 13.6. FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3423, 2955, 2930, 2872, 1941, 1716, 1436, 1322, 1268, 1133, 1062, 967, 853, 713; MS (EI, m/z): 254 (1, M<sup>+</sup>), 223 (1), 209 (2), 177 (4), 149 (3), 135 (4), 125 (6), 107 (8), 91 (7), 77 (10), 65 (5), 59 (10), 45 (100); HRMS (ESI): C<sub>14</sub>H<sub>23</sub>O<sub>4</sub> (M)<sup>+</sup>: 255.1591 (calculated), 255.1593 (found).



**2ia:** Yield: 26.4 mg (82%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 6.08 (d, *J*= 15.8 Hz, 1H), 5.72 (dd, *J*= 15.8, 6.8 Hz, 1H), 4.16 (q, *J*= 6.8 Hz, 1H), 3.70 (s, 3H), 2.31-2.15 (m, 4H), 1.62-1.28 (m, 16H), 0.93 (m, 9H); <sup>13</sup>C{1H} NMR: (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.1, 167.8, 132.8, 126.2, 108.2, 101.4, 73.1, 52.0, 37.0, 30.3, 29.6, 28.7, 28.3, 27.6, 22.6, 22.4, 22.3, 14.0, 13.9, 13.8; FTIR ( $\nu_{max}$ /cm<sup>-1</sup>): 3418, 2956, 2929, 2860, 1937, 1716, 1465, 1435, 1378, 1265, 1133, 1072, 964; MS (EI, m/z): 322 (1, M<sup>+</sup>), 236 (3), 194 (5), 163 (5), 119 (5), 105 (6), 91 (17), 85 (12), 69 (30), 57 (50), 41 (100); HRMS (ESI): C<sub>20</sub>H<sub>35</sub>O<sub>3</sub> (MH)<sup>+</sup>: 323.2581 (calculated), 323.2584 (found).



**2ia'**: Yield: 25.5 mg (80%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 6.08 (d, *J*= 15.7 Hz, 1H), 5.72 (dd, *J*= 15.7, 6.7 Hz, 1H), 4.17 (q, *J*= 6.7 Hz, 1H), 3.71 (s, 3H), 2.30-2.14 (m, 4H), 1.71-1.18 (m, 15H), 0.97-0.82 (m, 9H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.1, 167.8, 132.8, 126.1, 108.2, 101.4, 73.0, 52.0, 37.1, 30.4, 29.6, 28.7, 28.4, 27.6, 22.6, 22.4, 22.3, 14.0, 13.9; FTIR ( $\nu_{max}$ /cm<sup>-1</sup>): 3422, 2956, 2928, 2859, 1937, 1716, 1465, 1435, 1379, 1264, 1132, 1074, 963; MS (EI, m/z): 322 (1, M<sup>+</sup>), 236 (20), 231 (21), 205 (20), 195 (36), 194 (90), 179 (35), 177 (42), 165 (39), 163 (50), 152 (38), 135 (55), 121 (61),107 (68), 105 (60), 93(72), 91 (74), 85 (69), 79 (62), 57 (100), 55 (41); HRMS (ESI) C<sub>20</sub>H<sub>35</sub>O<sub>3</sub> (MH)<sup>+</sup>: 323.2581 (calculated), 323.2584 (found).



**2ja:** Yield: 20.7 mg (87%); <sup>1</sup>H NMR (400 MHz,  $C_6D_6$ )  $\delta$ : 6.16 (dd, *J*= 15.6, 1.2 Hz, 1H), 5.50 (dd, *J*= 15.6, 6.2 Hz, 1H, minor), 5.49 (dd, *J*= 15.6, 6.2 Hz, 1H, major), 4.03 (quint, *J*= 6.2 Hz, 1H), 3.38 (s, 3H, major), 3.37 (s, 3H, minor), 2.39 (td, *J*= 7.4, 1.2 Hz, 2H), 1.70 (s, 3H), 1.49-1.41 (m, 2H), 1.25 (sext, *J*= 7.4 Hz, 2H), 1.04 (d, *J*= 6.2 Hz, 3H), 0.80 (t, *J*= 7.4 Hz, 3H, minor), 0.80 (t, *J*= 7.4 Hz, 3H, major); <sup>13</sup>C{1H} NMR (100 MHz,  $C_6D_6$ )  $\delta$ : 213.3, 166.9, 134.7, 125.2, 103.1, 99.9, 68.0, 51.2, 30.3, 28.9, 23.1, 22.1, 14.5, 13.6; FTIR ( $v_{max}/cm^{-1}$ ): 3410, 2956, 2928, 1941, 1715, 1436, 1322, 1266, 1135, 1062, 1016, 965, 714; MS (EI, m/z): 238 (3, M<sup>+</sup>), 205 (5), 194,(15), 181 (15), 164 (13), 151 (55), 135 (45), 121 (100), 107 (30), 93 (90), 77 (45), 65 (10), 55 (14), 43 (92); HRMS (ESI):  $C_{14}H_{23}O_3$  (MH)<sup>+</sup>: 239.1648 (calculated), 239.1652 (found).



**2ka:** Yield: 29.9 mg (89%): <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.27 (dd, *J*= 15.8, 1.4 Hz, 1H, major), 6.26 (dd, *J*= 15.8, 1.4 Hz, 1H, minor), 5.78 (dd, *J*= 15.8, 5.5 Hz, 1H), 4.27-4.23 (m, 1H), 3.38 (s, 3H, major), 3.37 (s, 3H, minor), 3.05 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 3.02 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.94 (s, 3H), 2.46-2.41 (m, 2H), 2.34 (bs, 1H), 2.16-2.09 (m, 1H), 2.03-1.99 (m, 1H), 1.92-1.87 (m, 1H), 1.66-1.60 (m, 2H), 1.54-1.45 (m, 3H), 1.33-1.01 (m, 7H), 0.81 (t, *J*= 7.2 Hz, 3H, major), 0.81 (t, *J*= 7.2 Hz, 3H, minor); <sup>13</sup>C NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 212.3, 167.1, 129.0, 125.9, 113.8, 102.7, 76.5, 70.8, 58.2, 51.3, 38.0, 32.8, 32.4, 30.6, 29.0, 26.4, 26.4, 26.2, 22.4, 13.7; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3426, 2925, 2853, 1924, 1713, 1435, 1322, 1263, 1240, 1195, 1173, 1119, 1062, 1016, 964, 890, 841, 713; MS (EI, m/z): 336 (2, M<sup>+</sup>), 291 (60), 273 (8), 259 (100), 241 (20), 231 (30), 213 (27), 203 (30), 189 (19), 175 (21), 161 (22), 145 (21), 133 (21), 119 (19), 105 (25), 91(47), 79 (33), 67 (21), 55 (45), 45 (65); HRMS (ESI): C<sub>20</sub>H<sub>33</sub>O<sub>4</sub> (MH)<sup>+</sup>: 337.2380 (calculated), 337.2384 (found).



**2la:** Yield: 21.1 mg (68%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.22 (dd, *J*= 15.6, 1.6 Hz, 1H, major), 6.21 (dd, *J*= 15.6, 1.6 Hz, 1H, minor), 5.92 (dd, *J*= 15.6, 5.2 Hz, 1H), 4.23-4.15 (m, 1H), 3.38 (s, 3H), 3.01 (dd, A of ABX, *J*<sub>AB</sub>= 9.2 Hz, *J*<sub>AX</sub>= 3.6 Hz, 1H), 2.95 (dd, B of ABX, *J*<sub>AB</sub>= 9.2 Hz, *J*<sub>BX</sub>= 7.6 Hz, 1H), 2.92 (s, 3H), 2.44-2.37 (m, 2H), 2.29 (bs, 1H), 1.51-1.46 (m, 2H), 1.26 (sext, J=7.2 Hz, 2H), 1.07 (s, 9H), 0.81 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 208.6, 167.4, 132.0, 123.6, 117.1, 102.7, 76.4, 70.6, 58.2, 51.3, 33.8, 30.5, 30.1, 28.9, 22.4, 13.7; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3455, 2957, 2929, 2871, 1940, 1713, 1459, 1435, 1395, 1363, 1322, 1264, 1239, 1195, 1172, 1132, 1062, 1017, 963, 713; LC-MS/MS: 311 (67, MH<sup>+</sup>), 292 (19), 279 (80), 261 (27), 255 (10), 251 (5), 247 (10), 237 (9), 229 (60), 223 (100), 219 (8), 205 (8), 201 (9), 191 (8), 179 (26), 177 (8), 169 (10); HRMS (ESI): C<sub>18</sub>H<sub>31</sub>O<sub>4</sub> (MH)<sup>+</sup>: 311.2223 (calculated), 311.2220 (found).



**2ma:** Yield: 17.2 mg (81%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.29 (d, *J*= 16.0 Hz, 1H, major), 6.26 (d, *J*= 15.9 Hz, 1H, minor), 5.69-5.66 (m, 1H), 5.47 (ddd, *J*= 15.9, 5.2, 1.2 Hz, 1H), 4.17-4.12 (m, 1H), 3.32 (s, 3H, major), 3.31 (s, 3H, minor), 3.00 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 2.95 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.95 (s, 3H), 2.08 (bs, 1H), 1.55 (d, *J*= 2.7 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 216.1, 165.0, 130.2, 126.0, 103.5, 87.5, 76.3, 70.5, 58.2, 51.1, 14.0; FTIR ( $\nu_{max}/cm^{-1}$ ): 3429, 2925, 1944, 1721, 1438, 1395, 1260, 1196, 1153, 1126, 1028, 966, 840; MS (EI, m/z): 212 (2, M<sup>+</sup>), 193 (1), 167 (3), 135 (6), 110 (6), 107 (11), 81 (5), 77 (20), 67 (6), 59 (11), 45 (100); HRMS (ESI): C<sub>11</sub>H<sub>17</sub>O<sub>4</sub> (MH<sup>+</sup>): 213.1121 (calculated), 213.1120 (found).



**2na:** Yield: 27.0 mg (92%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.46 (dd, *J*= 15.7, 1.6 Hz, 1H), 5.53 (dd, *J*= 15.7, 5.5 Hz, 1H), 4.27-4.20 (m, 1H), 3.36 (s, 3H, major), 3.35 (s, 3H, minor), 3.05 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 3.00 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.96 (s, 3H), 2.64 (tt, *J*= 11.4, 3.4 Hz, 1H), 2.33 (bs, 1H), 1.95 (d, *J*= 11.4 Hz, 2H), 1.71 (s, 3H), 1.64-1.55 (m, 2H), 1.53-1.45 (m, 1H), 1.30-0.94 (m, 5H); <sup>13</sup>C NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 213.2, 166.6, 129.1, 105.9, 104.3, 76.5, 70.6, 58.2, 51.2, 37.6, 32.8, 26.4, 26.3, 26.0, 14.6; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3420, 2924, 2851, 1936, 1712, 1435, 1369, 1322, 1254, 1228, 1192, 1128, 1093, 1071, 1026, 997, 965, 891, 872, 780; MS (EI, m/z): 294 (2, M<sup>+</sup>), 262 (1), 249 (2), 217 (3), 189 (1), 171 (4), 135 (2), 119 (3), 105 (5), 91 (6), 77 (6), 67 (4), 55 (8), 45 (100); HRMS (ESI): C<sub>17</sub>H<sub>27</sub>O<sub>4</sub> (MH)<sup>+</sup>: 295.1904 (calculated), 295.1908 (found).



**20a:** Yield: 23.9 mg (89%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.43 (dd, *J*= 15.8, 1.6 Hz, 1H), 5.51 (dd, *J*= 15.8, 5.6 Hz, 1H), 4.25-4.20 (m, 1H), 3.32 (s, 3H, major), 3.30 (s, 3H, minor), 3.04 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.4 Hz, 1H), 2.99 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.96 (s, 3H), 2.34 (bs, 1H), 1.68 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 212.4, 165.9, 128.9, 108.8, 103.2, 76.5, 70.7, 58.2, 50.9, 34.2, 29.3, 14.6; FTIR ( $v_{max}$ /cm<sup>-1</sup>): 3419, 2955, 2870, 1934, 1717, 1435, 1362, 1322, 1258, 1226, 1132, 1062, 965; MS (EI, m/z): 268 (1, M<sup>+</sup>), 236 (1), 223 (2), 191 (3), 163 (5), 145 (5), 135 (15), 119 (5), 105 (6), 91 (12), 79 (15), 65 (5), 59 (7), 57 (25), 45 (100); HRMS (ESI): C<sub>15</sub>H<sub>25</sub>O<sub>4</sub> (MH)<sup>+</sup>: 269.1747 (calculated), 269.1748 (found).



**2ob:** Yield: 25.7 mg (91%): <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.44 (dd, *J*= 15.5, 1.6 Hz, 1H, major), 6.42 (dd, *J*= 15.5, 1.6 Hz, 1H, minor), 5.52 (dd, *J*= 15.5, 6.0 Hz, 1H), 4.23-4.19 (m, 1H), 3.95 (qd, *J*= 7.2 Hz, 1.2 Hz, 2H), 3.03 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 2.99 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.95 (s, 3H), 2.32 (bs, 1H), 1.70 (s, 3H), 1.31 (s, 9H), 0.89 (t, *J*= 7.2 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 212.1, 166.2, 129.0, 127.4, 109.2, 103.1, 76.5, 71.1, 60.3, 59.1, 34.2, 29.5, 14.8, 14.2; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3420, 2959, 1939, 1713, 1459, 1366, 1322, 1255, 1223, 1112, 1060, 965; MS (EI, m/z): 282 (2, M<sup>+</sup>), 249 (1), 237 (3), 208 (2), 191 (4), 163 (6), 135 (15), 105 (7), 91 (11), 77 (16), 65 (4), 57 (18), 45 (100); HRMS (ESI): C<sub>16</sub>H<sub>27</sub>O<sub>4</sub> (MH)<sup>+</sup>; 283.1904 (calculated), 283.1908 (found).



**20e:** Yield: 26.0 mg (88%) <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.43 (dd, *J*= 15.6, 1.6 Hz, 1H), 5.53 (dd, *J*= 15.6, 5.6 Hz, 1H), 5.01 (sept, *J*= 6.4 Hz, 1H), 4.22-4.19 (m, 1H), 3.03 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.4 Hz, 1H), 2.99 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.6 Hz, 1H), 2.95 (s, 3H, major), 2.94 (s, 3H, minor), 2.26 (bs, 1H), 1.71 (s, 3H), 1.31 (s, 9H), 1.00 (d, *J*= 6.4 Hz, 3H), 0.99 (d, *J*= 6.4 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 211.8, 165.9, 129.1, 127.3, 109.7, 103.1, 76.5, 71.1, 67.8, 59.0, 34.1, 29.5, 21.8, 21.8, 14.7; FTIR ( $v_{max}$ /cm<sup>-1</sup>): 3410, 2960, 2926, 2896, 2825, 1935, 1708, 1458, 1373, 1322, 1255, 1226, 1049, 1021, 964, 833, 783, 713; MS (EI, m/z): 296 (1, M<sup>+</sup>), 278 (1), 251 (2), 236 (2), 191 (6), 163 (7), 135 (15), 105 (14), 91 (17), 77 (16), 65 (5), 57 (40), 45 (100); HRMS (ESI): C<sub>17</sub>H<sub>29</sub>O<sub>4</sub> (MH)<sup>+</sup>: 297.2060 (calculated); 297.2064 (found).



**20g:** Yield: 25.9 mg (88%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.42 (dd, *J*= 15.6, 1.6 Hz, 1H, major), 6.40 (dd, *J*= 15.6, 1.6 Hz, 1H, minor), 5.64 (ddt, *J*= 17.2, 10.8, 4.8 Hz, 1H,), 5.53 (dd, *J*= 15.6, 5.6 Hz, 1H), 5.08 (dq, *J*= 17.2, 1.6 Hz, 1H), 4.87 (dq, *J*= 10.8, 1.6 Hz, 1H), 4.48-4.37 (m, 2H), 4.24-4.19 (m, 1H), 3.03 (dd, A of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 2.99 (dd, B of ABX, *J*<sub>AB</sub>= 9.6 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.95 (s, 3H, major), 2.94 (s, 3H, minor), 2.28 (bs, 1H), 1.69 (s, 3H), 1.30 (s, 9H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 212.4, 165.7, 132.5, 128.7, 127.7, 117.1, 108.9, 103.2, 76.5, 71.1, 64.7, 59.1, 34.2, 29.4, 14.8; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3410, 2957, 2927, 1935, 1713, 1647, 1457, 1398, 1362, 1321, 1252, 1217, 1172, 1131, 1061, 1027, 1016, 964, 928, 836, 781, 713; MS (EI, m/z): 294 (1, M<sup>+</sup>), 249 (3), 236 (2), 191 (4), 163 (5), 135 (6), 105 (5), 91 (10), 77 (9), 65 (3), 57 (16), 45 (100); HRMS (EI): C<sub>17</sub>H<sub>27</sub>O<sub>4</sub> (MH)<sup>+</sup>: 295.1904 (calculated), 295.1907 (found).



**2pa:** Yield: 29.6 mg (86%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 7.17-7.05 (m, 5H), 6.43 (dd, *J*= 15.8, 1.6 Hz, 1H), 5.49 (dd, *J*= 15.8, 5.6 Hz, 1H), 4.28-4.24 (m, 1H), 4.20 (s, 2H, major), 4.17 (s, 2H, minor), 3.31 (s, 3H), 3.19 (dd, A of ABX, *J*<sub>AB</sub>= 9.2 Hz, *J*<sub>AX</sub>= 3.6 Hz, 1H), 3.12 (dd, B of ABX, *J*<sub>AB</sub>= 9.2 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.32 (bs, 1H), 1.67 (s, 3H), 1.34 (s, 9H, minor), 1.29 (s, 9H, major); <sup>13</sup>C{1H} NMR: (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 212.4, 166.5, 137.8, 128.8, 128.5, 127.9, 127.8, 127.7, 108.8, 103.1, 74.0, 73.4, 71.2, 51.6, 34.2, 29.4, 14.8; FTIR ( $\nu_{max}$ /cm<sup>-1</sup>): 3422, 2954, 2865, 1934, 1715, 1496, 1479, 1454, 1434, 1391, 1362, 1257, 1225, 1104, 1060, 1029, 965, 781, 737, 698; MS (EI, m/z): 344 (2, M<sup>+</sup>), 311 (2), 296 (2), 223 (2), 191 (3), 168 (4), 135 (11), 107 (7), 91 (100), 57 (50), 41 (25); HRMS (ESI): C<sub>21</sub>H<sub>29</sub>O<sub>4</sub> (MH)<sup>+</sup>: 345.2060 (calculated), 345.2068 (found).



**2qa:** Yield: 22.1 mg (87%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.32 (dd, *J*= 15.8, 1.6 Hz, 1H, major), 6.09 (dd, *J*= 15.8, 6.0 Hz, 1H, minor), 5.74 (dd, *J*= 15.8, 1.6 Hz, 1H, minor), 5.43 (dd, *J*= 15.8, 6.0 Hz, 1H, major), 4.03-3.99 (m, 1H), 3.35 (dd, A of ABX, *J*<sub>AB</sub>= 11.2 Hz, *J*<sub>AX</sub>= 3.6 Hz, 1H), 3.32 (s, 3H), 3.23 (dd, B of ABX, *J*<sub>AB</sub>= 11.2 Hz, *J*<sub>BX</sub>= 7.2 Hz, 1H), 2.44 (bs, 1H), 2.22 (bs, 1H), 1.67 (s, 3H, major), 1.57 (s, 3H, minor), 1.34 (s, 9H, minor), 1.29 (s, 9H, major); <sup>13</sup>C NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 212.4, 165.9, 128.9, 108.9, 103.2, 72.8, 66.3, 50.9, 34.1, 29.3, 14.6; NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 212.4, 166.5, 129.2, 127.9, 108.9, 103.1, 73.0, 66.4, 51.7, 34.2, 29.4, 14.8; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3368, 2955, 2926, 2865, 1934, 1717, 1641, 1458, 1434, 1363, 1257, 1225, 1060, 1029, 965, 925, 862, 781; MS (EI, m/z): 254 (3, M<sup>+</sup>): 207 (7), 194 (11), 179 (10), 148 (13), 119 (15), 105 (20), 91 (35), 73 (20), 59 (20), 57 (100), 41 (50); HRMS (EI): C<sub>14</sub>H<sub>23</sub>O<sub>4</sub> (MH)<sup>+</sup>: 255.1591 (calculated), 255.1590 (found).



**2ra:** Yield: 30.9 mg, (84%): <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 6.43 (dd, *J*= 15.6, 1.6 Hz, 1H, major), 6.41 (dd, *J*= 15.6, 1.6 Hz, 1H, minor), 5.53 (dd, *J*= 15.6, 5.6 Hz, 1H), 4.17-4.12 (m, 1H), 3.42 (dd, A of ABX, *J*<sub>AB</sub>= 10.0 Hz, *J*<sub>AX</sub>= 4.0 Hz, 1H), 3.32 (dd, B of ABX, *J*<sub>AB</sub>= 10.0 Hz, *J*<sub>BX</sub>= 7.6 Hz, 1H), 3.32 (s, 3H), 2.23 (bs, 1H), 1.71 (s, 3H), 1.29 (s, 9H), 0.85 (s, 9H), -0.06 (s, 6H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 212.4, 165.9, 129.1, 108.8, 103.2, 72.5, 67.2, 50.9, 34.1, 29.3, 25.6, 18.1, 14.6, -5.6, -5.7; FTIR (v<sub>max</sub>/cm<sup>-1</sup>): 3467, 2954, 2927, 2857, 1935, 1718, 1462, 1434, 1362, 1256, 1225, 1111, 1062, 1005, 963, 837, 777; MS (EI, m/z): 368 (1, M<sup>+</sup>), 351 (1), 311 (3), 279 (2), 237 (10), 223 (8), 191 (10), 177 (15), 163 (20), 159 (43), 145 (20), 135 (25), 105 (30), 89 (45), 75 (85), 73 (100), 57 (55), 41 (38); HRMS (ESI): C<sub>20</sub>H<sub>37</sub>O<sub>4</sub>Si (MH)<sup>+</sup>: 369.2456 (calculated), 369.2463 (found).



**2sa:** Yield: 25.1 mg (87%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 7.71-7.67 (m, 2H), 7.14-7.11 (m, 2H), 7.03-6.99 (m, 1H), 6.41 (dd, *J*= 15.8, 1.2 Hz, 1H, major), 6.38 (dd, *J*= 15.8, 1.2 Hz, 1H, minor), 5.56 (dd, *J*= 15.8, 5.6 Hz, 1H), 4.21-4.16 (m, 1H), 3.38 (s, 3H, major), 3.36 (s, 3H, minor), 3.03-2.96 (m, 2H), 2.96 (s, 3H), 2.30 (bs, 1H), 1.68 (s, 3H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 215.9, 165.8, 133.2, 130.5, 128.7, 128.2, 127.5, 126.2, 104.4, 102.7, 76.4, 70.6, 58.2, 51.5, 14.2; FTIR ( $\nu_{max}/cm^{-1}$ ): 3419, 2922, 2851, 1926, 1716, 1492, 1434, 1369, 1321, 1273, 1195, 1171, 1123, 1062, 1039, 964, 918, 898, 781, 694; MS (EI, m/z): 288 (2, M<sup>+</sup>), 256 (3), 211 (5), 183(5), 155 (17), 115 (8), 89 (4), 77 (9), 51 (5), 45 (100); HRMS (ESI): C<sub>17</sub>H<sub>21</sub>O<sub>4</sub> (MH)<sup>+</sup>: 289.1434 (calculated), 289.1439 (found).



**2ta:** Yield: 25.4 mg (82%); <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 5.80 (d, *J*= 8.2, 1.6 Hz, 1H, minor), 5.75 (dt, *J*= 8.2, 1.6 Hz, 1H, major), 4.55-4.50 (m, 1H), 3.36 (s, 3H), 3.08-3.03 (m, 2H), 2.96 (s, 3H), 2.40 (td, *J*= 7.6, 2.8 Hz, 2H), 2.25-2.11 (m, 4H), 1.60-1.20 (m, 4H), 0.86-0.78 (m, 5H); <sup>13</sup>C{1H} NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 207.1, 167.4, 137.2, 125.6, 109.3, 99.6, 76.3, 66.9, 58.3, 51.4, 30.7, 30.5, 28.9, 28.5, 25.6, 25.5, 22.2, 13.9; FTIR ( $v_{max}$ /cm<sup>-1</sup>): 3456, 2928, 2857, 2859, 1946, 1713, 1436, 1436, 1266, 1241, 1128, 1063, 957; MS (EI, m/z): 308 (1, M<sup>+</sup>), 276 (25), 231 (65), 201 (35), 175 (40), 161 (50), 117 (55), 91 (95), 77 (40), 55 (30), 45 (100); HRMS (ESI): C<sub>18</sub>H<sub>29</sub>O<sub>4</sub> (MH)<sup>+</sup>: 310.2067 (calculated), 310.2067 (found).



**4ba:** M.P.: 67-69 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.38 (d, *J*=7.6 Hz, 2H), 7.32-7.28 (m, 2H), 7.06 (tt, *J*=7.6, 1.2 Hz, 1H), 6.72 (bs, 1H), 6.33 (dd, *J*=15.8, 1.2 Hz, 1H), 5.70 (dd, *J*= 15.8 Hz, 6.4 Hz, 1H), 5.53 (qd, *J*= 5.6, 1.2 Hz, 1H), 3.70 (s, 3H), 3.60 (d, *J*=2.4 Hz, 1H), 3.59 (d, *J*=0.8 Hz, 1H), 3.42 (s, 3H), 2.25 (t, *J*= 7.6 Hz, 2H), 1.89 (s, 3H), 1.40-1.28 (m, 4H), 0.88 (t, *J*= 7.6 Hz, 3H); <sup>13</sup>C{1H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 213.8, 167.5, 152.6, 137.7, 130.0, 129.1, 124.8, 123.5, 118.6, 103.0, 100.0, 74.1, 73.5, 59.3, 52.1, 30.1, 28.6, 22.1, 14.7, 13.9.

# **CHAPTER 4**

# **RESULTS AND DISCUSSION**

We initiated our study using the enyne oxirane (*Z*)-**1a** whose oxirane terminus is dimethyl substituted. We were pleased to observe that, with just our first attempt, the substrate (*Z*)-**1a** was converted to the desired 2,3,5-trienoate product **2aa**, which is exclusively in (*E*)-configuration, and carries a hydroxyl group on the allylic position, almost quantitatively under very mild reaction conditions; the conversion was complete within just 1 h, when the reaction was performed in the presence of a Pd<sub>2</sub>(dba)<sub>3</sub>-CHCl<sub>3</sub> (0.5 mol % Pd) and PPh<sub>3</sub> (2 mol %) combination in MeOH, and under balloon pressure of CO at 25 °C (Table 4.1, entry 1). The catalyst loading could even be reduced by half (0.25% Pd, 1% PPh<sub>3</sub>) without compromising the product yield (entry 2). The optimum PPh<sub>3</sub>/Pd ratio appears to be 4:1, because any deviation from this ratio resulted in a decrease in the reaction rate (entries 1-4). Finally, the controlled experiments proved that no conversion for the substrate would be possible in the absence of a phosphine ligand or a palladium source (entries 5 and 6).

Table 4.1. Methoxycarbonylation of Enyne Oxirane (Z)-1a.<sup>a</sup>

Me		Me
	Pd <sub>2</sub> (dba) <sub>3</sub> -CHCl <sub>3</sub> , PPh <sub>3</sub>	Bu
Bu Me	MeOH, CO	СО <sub>2</sub> Ме ОН
(Z) <b>-1a</b> <sup>Me</sup>		2aa

entry	Pd %	PPh <sub>3</sub> %	<i>t</i> (h)	yield% <sup>b</sup>
1	0.5	2	1	>99°
2	0.25	1	2	>99
3	0.5	3	3	>99
4	0.25	0.5	5	>99
5	1	0	16	0
6	0	4	16	0

<sup>a</sup>Reaction conditions: 0.3 mmol of (*Z*)-**1a**, 2 mL of MeOH, under CO filled balloon, 25 °C. <sup>b</sup>Determined by <sup>1</sup>H NMR analysis using benzaldehyde as the internal standard. <sup>c</sup>Isolated yield.
Having determined that the enyne oxirane (*Z*)-1a is a perfectly amenable reagent toward palladium catalysis as a means to synthesize vinylallene structures, we next probed the diastereoselectivity—directly associated with the level of center-to-axial chirality transfer—of the method over the substrate (*Z*)-1b, using a variety of mono- and bidentate ligands. The corresponding vinylallene product 2ba was in 96% yield with a good diastereomeric ratio (92:8) when PPh<sub>3</sub> was used as the ligand (Table 4.2, entry 1). The relative configuration of its major diastereomer was determined by X-ray crystallography of its phenylcarbamate derivative (Figure 4.1), (Kuş, *et al.* 2015).



Figure 4.1. X-ray crystallographic structure of the phenylcarbamate derivative of 2ba.

Typically, comparable yields are obtained with a variety of monodentate phosphine ligands tested herein, with varying reaction times required for a full conversion. However, it has been found that the level of the chirality transfer is strongly dependent on the ligand type that is used. The reactions in the presence of a prepared catalyst Pd(PPh<sub>3</sub>)<sub>4</sub> or P(2-MeC<sub>6</sub>H<sub>4</sub>)<sub>3</sub> ligand proceeded with similar selectivities when compared with PPh<sub>3</sub> (entries 2 and 3), whereas electron rich phosphines and a heteroaryl substituted phosphine all showed inferior stereoselectivities (entries 4-7). The best diastereoselectivity was obtained with the use of an electron poor phosphine ligand, P(4-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>)<sub>3</sub>, which afforded **2ba** with 94% yield and 94:6 diastereoselective ratio (dr) within just 30 min (entry 8). Finally, the use of bidentate ligands brought about dismal selectivities or low activities in some cases (entries 9-14).

(Z)- <b>1b</b>		2ba	
ligand	<i>t</i> (h)	yield% <sup>b</sup>	dr <sup>c</sup>
PPh <sub>3</sub>	1	96	92:8
$PPh_3^d$	4	89	92:8
$P(2-MeC_6H_4)_3$	0.5	92	92:8
$P(2-OMeC_6H_4)_3$	0.5	97	87:13
$P(4-OMeC_6H_4)_3$	1	95	86:14
PPh <sub>2</sub> Me	2.5	81	80:20
Tris(2-furyl)phosphine	1	94	83:17
$P(4-CF_{3}C_{6}H_{4})_{3}$	0.5	94 <sup>e</sup>	94:6
dppf	1	72	90:10
dppe	3	96	86:14
dppb	1.5	89	86:14
Xantphos	1.5	92	86:14
(±)-BINAP	9.5	$44^{f}$	85:15
BIPHEP	10	0	-
	(Z)-1b ligand PPh <sub>3</sub> PPh <sub>3</sub> <sup>d</sup> P(2-MeC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> P(2-OMeC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> P(4-OMeC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> P(4-OMeC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> PPh <sub>2</sub> Me Tris(2-furyl)phosphine P(4-CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> dppf dppe dppb Xantphos ( $\pm$ )-BINAP BIPHEP	Iigand $t$ (h)PPh31PPh3d4P(2-MeC_6H4)30.5P(2-OMeC_6H4)30.5P(4-OMeC_6H4)31PPh2Me2.5Tris(2-furyl)phosphine1P(4-CF3C6H4)30.5dppf1dppe3dppb1.5Xantphos1.5(±)-BINAP9.5BIPHEP10	(Z)-1b Owne 2ba   ligand t (h) yield% <sup>b</sup> PPh3 1 96   PPh3 <sup>d</sup> 4 89   P(2-MeC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> 0.5 92   P(2-OMeC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> 0.5 97   P(4-OMeC <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> 1 95   PPh <sub>2</sub> Me 2.5 81   Tris(2-furyl)phosphine 1 94   P(4-CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> 0.5 94 <sup>e</sup> dppf 1 72   dppe 3 96   dppb 1.5 89   Xantphos 1.5 92   (±)-BINAP 9.5 44 <sup>f</sup> BIPHEP 10 0

Table 4.2. The Effect of Ligand on Methoxycarbonylation of (*Z*)-1ba.

Pd<sub>2</sub>(dba)<sub>3</sub>-CHCl<sub>3</sub>, Ligand

MeOH, CO

Me

MeO<sub>2</sub>C<sup>w</sup>

Bu

OMe

ŌΗ

<sup>a</sup>Reaction conditions: 0.1 mmol of (*Z*)-**1b**, 2 mL of MeOH, 1 mol % of Pd, P/Pd ratio is 4:1, under CO filled balloon, 25 °C. dppf: 1,1'-bis(diphenylphosphino)ferrocene; dppe: 1,2-bis(diphenylphosphino)ethane; dppb: 1,4bis(diphenylphosphino)butane; Xanthphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; BINAP: 2,2'bis(diphenylphosphino)-1,1'-binaphthalene; BIPHEP: 2,2'-bis(diphenylphosphino)-1,1'-biphenyl. <sup>*b*</sup>Determined by <sup>1</sup>H NMR analysis using benzaldehyde as the internal standard. <sup>*c*</sup>Diastereomeric ratio (dr) was determined by <sup>1</sup>H NMR. <sup>*d*</sup>Pd(PPh<sub>3</sub>)<sub>4</sub> was the catalyst of this reaction. <sup>e</sup>Isolated yield. <sup>*f*</sup>The conversion of (*Z*)-1b was 49%.111

Having determined  $P(4-CF_3C_6H_4)_3$  as the optimal ligand, next we explored the suitability of a number of alcohol reagents for their reactions with (*Z*)-**1b**. Except those with *t*-BuOH (Table 4.3, entry 5), the vinylallene products could be obtained at yields within the range of 83-91% with all alcohol reagents tested herein. Surprisingly, however, the reactions performed with alkyl alcohols, including EtOH, PrOH, BuOH, and *i*-PrOH; all proceeded with relatively lower stereoselectivities (entries 1-5). Nevertheless, gratifyingly an additional functionality could be introduced to a 7-hydroxy-2,3,5-trienoate structure with the use of allyl alcohol, which yielded the corresponding product **2bg** in 91% yield and with 93:7 dr, albeit with higher Pd loading to complete the reaction (entries 6-7).

Me	H			Me	
		(dba) <sub>3</sub> -CHCl <sub>3</sub> , P(4-C	F <sub>3</sub> C <sub>6</sub> H <sub>4</sub> ) <sub>3</sub> ────────────────────────────────────	2C	OMe
Bu (7)- <b>1</b> b		ROH, CO		Bu OH	
entry	ROH	product	t (h)	yield %	dr <sup>b</sup>
1	EtOH	<b>2</b> bb	1	84	80:20
2	PrOH	2bc	3	87	88:12
3	BuOH	2bd	4	83	86:14
4	<i>i</i> -PrOH	2be	2	88	86:14
5	t-BuOH	2bf	10	0	-
6 <sup><i>c</i></sup>	Allyl		6	25	93:7
$7^d$	alcohol	2Dg	1	91	93:7

Table 4.3. Alkoxycarbonylation of Enyne Oxirane (Z)-1a.<sup>a</sup>

<sup>*a*</sup>Performed under the conditions of Table 4.2. <sup>*b*</sup>Determined by <sup>1</sup>H NMR. <sup>*c*</sup>Conversion of (Z)-**1b** was 75%. <sup>*d*</sup>Reaction was performed with 3 mol % of Pd and 12 mol % of ligand.

It seems that the method is also suitable for enyne oxiranes containing an (*E*)configured alkenyl moiety; a carbonylation reaction of (*E*)-**1b** in MeOH under the standard conditions (conditions denoted in Table 4.2) required remarkably longer reaction period for complete conversion, and resulted in a diastereomer of **2ba** (**2ba'**) with a high yield, but slightly decreased selectivity of 92:8 dr (Figure 4.2). This result also proves that the configuration of alkenyl moiety of substrate regulates the stereomeric outcome of the product. Nonetheless, because of some difficulties encountered during the synthesis of enyne oxiranes with (*E*)-alkenyl group, such as partial isomerization of the alkenyl group, further studies were continued using only (*Z*)-configured reagents.



Figure 4.2. Methoxycarbonylation of (*E*)-1b

Next we explored the scope of the protocol over a variety of substrates containing (Z)-alkenyl and (E)-oxirane moieties. Except in one case, alkoxycarbonylation reactions proceeded rather smoothly and provided the expected products at yields within the range of 81-92%.

It was interesting to observe that the form of pendant oxygen functionality within  $R^3$  group is an important factor for the stereoselectivity of the process. Substituting the methoxymethyl group in  $R^3$  position with a benzyloxymethyl group ((*Z*)-1c) had no detectable effect on both the reactivity and stereoselectivity (Table 4.4, entry 1). However, when  $R^3$  was a carbinol group ((*Z*)-1d) or its hydroxyl group was silyl protected ((*Z*)-1e), the corresponding methoxycarbonylated products 2da and 2ea were obtained with 90:10 and 89:11 dr, respectively (entries 2 and 3).

The same trend was also obvious for the reactions of (*Z*)-**1f** and (*Z*)-**1g**, where  $\mathbb{R}^3$  is dimethylcarbinol and dimethylmethoxy methyl, respectively. Though comparably good yields could be achieved with both reagents, the products **2fa** and **2ga** were obtained with significantly different level of stereoselectivities, 85:15 and 95:5 dr, respectively (entries 4 and 5).

It seems that for an effective stereoselectivity, the alkenyl carbon that is proximal to the alkynyl moiety is required to be fully substituted, because the carbonylative reaction of the enyne oxirane containing a disubstituted alkenyl moiety ((*Z*)-**1h**) with MeOH proceeded with an inferior stereoselectivity (entry 6). As a model for substrates with all alkyl substituents, the enyne oxirane (*Z*)-**1i**, where all  $\mathbb{R}^1$ ,  $\mathbb{R}^2$ , and  $\mathbb{R}^3$  positions were occupied by butyl groups, also gave rise to the expected product **2ia** with a high selectivity of 93:7 dr (entry 7). However, (*Z*)-**1j** possessing a methyl group in the  $\mathbb{R}^3$  interestingly afforded the lowest dr (82:18) as compared to other enyne oxiranes tested herein (entry 8). While the method tolerated a larger cyclohexyl group in the  $\mathbb{R}^2$  (entry 9) under the reaction conditions, the presence of the *tert*-butyl group at this position ((*Z*)-**1l**) brought about the formation of an allylic esterified byproduct (**3la**) along with the desired product **2la** with a high dr (entry 10).

It was also intriguing to find that there appears to be a direct relation between the diastereoselectivity and the size of  $\mathbb{R}^1$  (entries 11-13). For instance, when (*Z*)-**1m**, which contains a terminal alkynyl moiety, was subjected to the methoxycarbonylation, the product **2ma** was obtained with only 88:12 dr Nevertheless, the substrate (*Z*)-**1o** ( $\mathbb{R}^1 = t$ -Bu) afforded the expected product **2oa** in an excellent level of selectivity (97:3 dr).

The remarkable improvement on the stereoselectivity of the process that was gained with the presence of the *tert*-butyl group on the alkynyl moiety appears enduring; in contrast to the results obtained with (*Z*)-**1b**, when  $R^1 = tert$ -butyl, the replacement of the methoxy group with benzyloxy ((*Z*)-**1p**), hydroxyl ((*Z*)-**1q**), or silyl protected ((*Z*)-**1r**) groups within  $R^3$  only slightly impacted the dr of the corresponding products (entries 14-16).



Table 4.4. Alkoxycarbonylation of Enyne Oxiranes.<sup>a</sup>

### Table 4.4. (cont.)







MeO<sub>2</sub>C<sub>///→</sub> Bu → → → → → → → → → → → Me 87 82/18 Hồ 2ja



MeO<sub>2</sub>C<sub>4,...</sub> Bu OMe 68 95/5



+ t-Bu HeO<sub>2</sub>C OMe **3la** OH







(cont. on next page)

#### Table 4.4. (cont.)



<sup>a</sup>Performed under the conditions of Table 4.2. <sup>b</sup>Determined by <sup>1</sup>H NMR. <sup>c</sup>Not determined.

The envne oxirane (Z)-1s with a phenyl substituent at alkynyl terminus yielded the product 2sa with 88:12 dr (entry 20), and the substrate 1t having an endocyclic double bond also successfully underwent methoxycarbonylation to generate an exocyclic conjugated vinylallene structure 2ta with a relatively lower but synthetically still useful dr (Figure 4.3).



Figure 4.3. Methoxycarbonylation of (*Z*)-1t

Moreover, the carbonylative reaction of (Z)-10 with other alcohols also provided the corresponding vinylallenes with high dr values (Table 4.5).

	t-Bu H (Z)- <b>10</b> Me H H (Z)- <b>10</b>	Conditions for Ta ROH, CO ⁄le	RO <sub>2</sub> C <sub>رم</sub> able 4.2 Bu	HO 20	
entry	ROH	product	t (h)	yield %	dr <sup>b</sup>
1	EtOH	20b	2	91	95:5
2	<i>i</i> -PrOH	<b>2</b> 0e	3	88	94:6
3°	Ally alcohol	<b>2</b> 0g	1	88	95:5

Table 4.5. Alkoxycarbonylation of Enyne Oxirane (Z)-10.<sup>a</sup>

<sup>*a*</sup>Performed under the conditions of Table 4.2. <sup>*b*</sup>Determined by <sup>1</sup>H NMR. <sup>c</sup>Reaction was performed with 3 mol % of Pd and 12 mol % of ligand.

The mechanisms illustrated in Figure 4 are proposed to account for the stereoselective formation of **2** and **2'**. The reaction cycle should begin with ring-opening by the attack of a palladium complex to both (*Z*)-1 and (*E*)-1 in *anti*-mode, leading to the formation of  $\pi$ -allylpalladium complexes **A** and **A'**, respectively, given the formation of vinylallenes exclusively in (*E*)-configuration for both intermediates (**A** and **A'**), the alkanolate group (CHR<sup>3</sup>O') on the planar allyl ligand should be oriented *syn* with respect to the middle allylic C-H. These intermediates additionally undergo a palladium shift to the far alkynyl carbon proceeding mainly with retention to form vinylallenyl palladium complexes **B** and **B'**, respectively. The relative position of the R<sup>2</sup> group and alkynyl moiety on **A** and **A'** may also be inverted via the  $\pi$ - $\sigma$ - $\pi$  interconversion into **C** and **C'**, respectively, before undergoing such a Pd shift. The favored configuration of this side of the complex should be regulated by the inherent structure of R<sup>2</sup>. For instance when R<sub>2</sub> is hydrogen the thermodynamically more stable  $\pi$ -allyl complexes should bear alkynyl and CHR<sup>3</sup>O' moieties in *syn*, *syn* positions (**A'** and **C**).



Figure 4.4. The Mechanism of Alkoxycarbonylation of Conjugated Enyne Oxiranes.

However, such configurational transitions cannot alter the outcome of the reaction, because both isomeric intermediates C and C' would also lead to B and B', respectively. These  $\sigma$ -allenylpalladium complexes undergo successive CO insertion and reductive elimination, as verified previously, to yield 2 and 2' stereoselectively.

The loss of stereochemical integrity of the resulting products should take place during the course of the reaction cycle because subjecting the purified **2ba** again to the standard conditions for 4 h had no influence on its original diastereomeric ratio. Though we cannot completely disregard the occurrence of the  $\pi$ -allylpalladium isomerization or its formation through *syn*-attack of the palladium, the back side migration of the palladium over the alkynyl side (by inversion of configuration) could be the primary basis for the formation of the minor diastereomeric form in each case, and particularly increased sizes of R<sup>1</sup> and R<sup>2</sup> might have limited the occurrence of such transitions in an inverted manner. However, the presence of a highly encumbered group, such as *tert*-butyl, at R<sup>2</sup> also retards the effective migration of the  $\pi$ -allyl coordinated palladium, and as a result (*Z*)-**11** partly underwent allylic alkoxycarbonylation to form the byproduct **3la**. Finally, the envne oxirane (*Z*)-1i' containing a (*Z*)-configured oxirane moiety was also the subjected to the standard reaction conditions. The reaction proceeded smoothly in accordance to the proposed mechanism, and thus yielded the vinylallene product **2ia**', which is the diastereomer of **2ia** (see entry 7 of Table 4.4), with a high level of dr (Figure 4.5).



Figure 4.5. Methoxycarbonylation of (*Z*)-1i.

# **CHAPTER 5**

## CONCLUSION

In summary, we have developed a mild, simple and atom economical method for the synthesize of *anti*-substituted (*E*)-configured vinylallenes bearing a hydroxyl group on the allylic position via palladium-catalyzed alkoxycarbonylative 1,5-substitution reactions of conjugated enyne oxiranes.

The optimization studies showed that the reactions can be performed in the presence of  $Pd_2(dba)_3$ -CHCl<sub>3</sub> catalyst, an electron poor phosphine ligand,  $P(4-CF_3C_6H_4)_3$ , and balloon pressure of carbon monoxide, which afforded the desired vinyallene structures with good yields and diastereoselectivities.

The reactions proceeded in a highly stereoselective manner, possibly through sequential formation of  $\pi$ -allylpalladium and  $\sigma$ -vinylallenyl palladium complexes and the major diastereometric form of the product is determined by the configuration of the alkenyl moiety of the substrate.

### REFERENCES

- Akpınar, G. E.; Kuş, M.; Üçüncü, M.; Karakuş, E.; Artok, L. Org. Lett. 2011, 13, 748-751.
- Alper, H.,; Yu, W. Y. J. Org. Chem. 1997, 62, 5684-5687.
- Betzer, J. F.; Delaloge, F.; Muller, B.; Pancrazi, A.; Prunet, J. J. Org. Chem. 1997, 62, 7768-7780.
- Bond, D. J. Org. Chem. 1990, 55, 661-665.
- Buss, A. D.; Warren, S. J. Chem. Soc. Perkin Trans. I 1985, 2307-2325.
- Caldentey, X. C.; Cambeiro, X. C.; Pericàs, M. *Tetrahedron* **2011**, 67, 4161-4168.
- Chen, Z.; Duan, X.; Wu, L.; Ali, S.; Ji, K.; Zhou, P.; Liu, X.; Liang, Y. *Chem. Eur. J.* **2001**, 17, 6918-6921.
- Denmark, S. E.; Wang, Z. Org. Synth. 2005, 81, 42-52
- Elsevier, C.J.; Kleijin, H.; Boersma, J.; Vermeer, P. Organometallics 1986, 5, 716-720.
- Fang, Z.; Liao, P. C.; Yang, Y. L.; Yang, F. L; Chen, Y. L.; Lam, Y.; Hua, Y. F.; Wu, S. H. J. Med. Chem. 2010, 53, 7967-7978.
- Gore, J.; Dulcere, J.P. J. Chem. Soc. Chem. Comm. 1972, 867.
- Kajikawa, T.; Aoki, K.; Singh, R. S.; Iwashita, T.; Kusumoto, T.; Frank, H.A.; Hashimoto, H.; Katsumura, S. *Org. Biomol. Chem.* **2009**, 7, 3723-3733.
- Krause, N.; Purpura, M. Eur. J. Org. Chem. 1999, 1, 265-275.
- Kuş, M.; Artok, L.; Aygün, M. J. Org. Chem. 2015, 80, 5494-5506. (CCDC 1019595 contains the supplementary crystallographic data of phenylcarbamate derivative of 2ba. This data can be obtained free of charge from The Cambridge Crytallographic Data Centre via www.ccdc.cam.ac.uk/data\_request/cif)
- Lian, J. J.; Chiang, P. C.; Lin, Y. P.; Ting, H. C.; Liu, R. S. J. Am. Chem. Soc. 2006, 128, 11372-11373.

Ma, S.; Wang, G. Angew. Chem. Int. Ed. 2003, 42, 4215-4217.

Marshall, J. A.; Wolf, M. A.; Wallace, E. M J. Org. Chem. 1997, 62, 367-371.

- Meijere, A.; Diederich de F. Metal-Catalyzed Cross-Coupling Reactions. Volume 1: WILEY-VCH Verlag GmbH & Co. KgaA, **2004**.
- Ming-Yuan, L.; Madhushaw, R. J.; Liu, R. S. J. Org. Chem. 2004, 69, 7700-7704.
- Molander, G. A.; Sommers, E.M.; Baker, S. R. J. Org. Chem. 2004, 71, 1563-1568.
- Murahashi, S. I.; Imoda, Y.; Taniguchi, Y.; Higashiura, S. J. Org. Chem. **1993**, 58, 1538-1545.
- Piers, E.; Wong, T.; Coish, P.; Rogers, C. Can. J. Chem. 1994, 72, 1816-1819.
- Sakamoto, M.; Shimizu, I.; Yamamoto, A. Bull. Chem. Soc. Jpn. 1996, 69, 1065-1078.
- Satoh, T.; Ikeda, M.; Kushino, Y.; Miura M.; Nomura, M. J. Org. Chem., **1997**, 62, 2662-2664.
- Schmidt, B.; Pohler, M.; Costisella, B. Tetrahedron 2002, 58, 7951-7958.
- Shimizu, I.; Maruyama, T.; Makuta, T.; Yamamoto, A. *Tetrahedron Lett.* **1993**, *34*, 2135-2142.
- Stille, J. K., Simpson, J. H. J. Am. Chem. Soc. 1987, 109, 2138-2152
- Trost, B. M.; Molander, G. A. J. Am. Chem. Soc. 1981, 103, 5969.
- Tsuji, J;, Kataoka, H.; Kobayashi, Y. Tetrahedron Lett. 1981, 22, 2575.
- Tsuji, J.; Sato, K.; Okumoto, H. J. Org. Chem. 1984, 49, 1341-1344.
- Tsuji, J.; Watanabe, H.; Minami, I.; Schmizu, I. J. Am. Chem. Soc. 1985, 107, 2196-2198.
- Tsuji, J.; Sugiura, T.; Minami, I. Tetrahedron Lett. 1986, 27, 731-734.
- Tsuji, J.; Suqiura, T.; Yuhara, M.; Minami, I. J. Chem. Soc. Chem. Comm. 1986, 922-924.

Tsuji, J.; Mandai, T. J. Organomet. Chem. 1993, 451, 1-15.

Tsuji, J.; Mandai T. Angew. Chem. Int. Ed. 1995, 34, 2589-2612.

- Tsuji, J. Palladium Reagents in Organic Synthesis; John Wiley and Sons: New York, **1995**: 453-471.
- Tsuji, J., Palladium Reagents and Catalysts-New Perspectives for the 21st Century: WILEY-VCH Verlag GmbH & Co. KgaA, 2004.
- Ukai, T.; Kawazura, H.; Ishii, Y.; Bonnet, J. J.; Ibers, J. A. J. Organomet. Chem. 1974, 65, 253-266.
- Urabe, H.; Suzuki, K.; Sato, F. J. Am. Chem. Soc. 1997, 119, 10014-10027.
- Üçüncü, M.; Karakus, E.; Kuş, M.; Akpınar, G.E.; Aksın-Artok, Ö.; Krause, N.; Karaca, S.; Elmacı, N.; Artok, L. *J. Org. Chem.* **2011**, 76, 5959–5971.
- Wang, C.; Tobrman, T.; Xu, Z.; Negishi, E. Org. Lett. 2009, 11, 4092-4095

# **APPENDIX A**

# 1H NMR and 13C NMR SPECTRUMS OF REACTANTS AND PRODUCTS



#### MK-la



ΓΓ







![](_page_92_Figure_0.jpeg)

![](_page_93_Figure_0.jpeg)

![](_page_94_Figure_0.jpeg)

![](_page_95_Figure_0.jpeg)

![](_page_96_Figure_0.jpeg)

MK-05-11-12-8AF-T

![](_page_97_Figure_0.jpeg)

![](_page_98_Figure_0.jpeg)

![](_page_99_Figure_0.jpeg)

![](_page_100_Figure_0.jpeg)

![](_page_101_Figure_0.jpeg)

![](_page_102_Figure_0.jpeg)

![](_page_103_Figure_0.jpeg)

![](_page_104_Figure_0.jpeg)

Acquisition Time (sec)	2.5559	Comment	mk-bu-y	Date	Jun 29 2013	Date Stamp	Jun 29 2013
File Name	C:\USERS\FiRAT	DESKTOP/EPOXIDE/21	0T092-FINAL RAPOR	RUNMR FIDS/MELIH/M	K-BU-Y_20130629	02\PROTON_01.FID\FID	
Frequency (MHz)	399.92	Nucleus	1H	Number of Transients	8	Original Points Count	16384
Points Count	16384	Pulse Sequence	s2pul	Receiver Gain	46.00	Solvent	BENZENE-d6
Spectrum Offset (Hz)	2399.5100	Spectrum Type	STANDARD	Sweep Width (Hz)	6410.26	Temperature (degree C	25.000
PROTON_01 1.00 0.95 0.90 0.85 0.80 0.75 0.70 0.65 0.60 0.55 0.60 0.55 0.20 0.45 0.30 0.25 0.30 0.25 0.30 0.25 0.30 0.55 0.55 0.30 0.55 0	Vertica	IScaleFactor = 1	Bu (Z)-	Bu H H H H	3,838	2.724 2.718 -2.696 -2.696 -2.696 -2.128 -2.111 -2.078 -2.111	1543 1.123 1.120 1.1195 1.1195 1.112 1.122 1.122 1.122 1.122 1.122 1.122 1.122 1.122 1.122 1.122 1.122 1.133 0.703 0
8.0 7.1	5 7.0	6.5 6.0	1.00 U 5.5 5.0	0. 4.5 4.0 Chemical Sh	98 J 3.5 ift (pom)	1.08 3.81 3.0 2.5 2.0	17.28 11.05 1.5 1.0 0.5 0

![](_page_106_Figure_0.jpeg)

![](_page_107_Figure_0.jpeg)








































## 07.08.2014-14.06.53

Acquisition Time (sec)	2.5559	Comment	Gradient Shimmi	ng		Date	Oct 25 20 13
Date Stamp	Oct 25 2013	File Name	CAUSERS/FIRA	TOESKTOP'MELIH'MK-2	5101 20131025	01/PROTON 01.FID/FID	
Frequency (MHz)	399.92	Nucleus	<u>1H</u>	Number of Transients	8	Original Points Count	16384
Points Count	16384	Pulse Sequence	s2pul	Receiver Gain	50.00	Solvent Toologia	CHLOROFORM4d
Spectrum Offset (Hz)	2399.5020	j Spectrum (ype	SLANDARD	Sweep waan (Hz)	<u>6410.26</u>	i remperature (degree C)	
PROTON_01	Vertic	alScaleFactor = 1			e F		
			^	0			
				OMe			
				<u></u>			
0.90			(7) <b>_1</b>	t Bu			
0.75			(~)-1	•			
0.70							
0.65							
.≩0.60							8
<u>§</u> 0.55							동 연
							۲
Ê 0.46					I		
2 0.40							28 T 888
0.35						ž	
0.30					ä,	្ដ្រី	
0.25					342	<sup>7</sup> 8	22 4 4 5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
0.20		8			200		
U.10		13			22 27 20 20 20 20 20 20 20 20 20 20 20 20 20	27 T	
0.05						M M	M M ( V ) )
						Vlue Vl	
Ĩ					1.03 1.13 4.0	ວາ <u>ໄ</u> ຮ 2.152.31	212 7.40 5.06
9D 85 8D 75 7.0 65 6.0 55 5.0 45 4D 3.5 3D 25 2D 1.5 1D 0.5 0 -0.5 Chemical Shift(ppm)							














































Gradient Shimming







MK-1307CO








































































# **APPENDIX B**

# MASS SPECTRUMS OF PRODUCTS



MK-M24 #2847 RT: 15.68 AV: 1 NL: 3.13E8 T: {0,0} + c El Full ms [40.00-500.00] 100 43.1



MK-M7 #3407 RT: 17.58 AV: 1 NL: 2.44E6 T: {0,0} + c EI Full ms [40.00-500.00]



MK-M7 #3407 RT: 17.58 AV: 1 NL: 2.44E6 T: {0,0} + c EI Full ms [40.00-500.00]











MK-M18 #3480 RT: 17.83 AV: 1 NL: 7.98E6 T: {0,0} + c EI Full ms [40.00-500.00] 100-<sup>45.2</sup>







MK-M23 #4272 RT: 20.52 AV: 1 NL: 3.46E6 T: {0,0} + c EI Full ms [40.00-500.00] 100-75.1



MK-M4 #3661 RT: 18.45 AV: 1 NL: 1.79E6 T: {0,0} + c EI Full ms [40.00-500.00]



MK-M6 #3705 RT: 18.60 AV: 1 NL: 9.65E7 T: {0,0} + c EI Full ms [40.00-500.00] 100-73.2













ea-m26#165-211 RT: 2.14-2.74 AV: 47 SB: 40 1.16-1.67 NL: 1.22E4 T: + c ESI [ 50.00-1000.00]


















MK-M16 #3973 RT: 19.51 AV: 1 NL: 3.05E8





MK-M25-2 #4293 RT: 20.60 AV: 1 NL: 9.16E7 T: {0,0} + c EI Full ms [40.00-500.00]

# <u>MELİH KUŞ</u>

Place of Birth / Date: Izmir / 1984

## **RESEARCH**

Transition metal catalyzed C-C bond forming reactions, new reaction strategies

### **EDUCATION**

2009-2015	Doctor of Philosophy: The Graduate School of Engineering and Sciences
	Izmir Institute of Technology
2007-2009	Master of Science: The Graduate School of Engineering and Sciences
	Izmir Institute of Technology
2002-2007	Bachelor of Science: Department of Chemistry-Izmir Institute of
	Technology

### **PUBLICATIONS**

- Kus, M.; Artok, L.; Aygün, M. Palladium-Catalyzed Alkoxycarbonylation of Conjugated Enyne Oxiranes: A Diastereoselective Method in Synthesis of 7-Hydroxy-2,3,5-Trionates *J. Org. Chem.*, 80, 5494-5506, 2015.

- Karagöz, E.S.; Kus, M.; Akpinar, G.E.; Artok, L. Regio- and Stereoselective Synthesis of 2,3,5-Trionates by Palladium Catalyzed Alkoxycarbonylation of Conjugated Enyne Carbonates *J. Org. Chem.*, 79, 9222-9230, 2014.

- Üçüncü, M.; Karakus, E.; Kus, M.; Akpınar, G. E.; Aksın-Artok, Ö.; Krause, N.; Karaca, S.; Elmacı, N.; Artok, L. Rhodium- and Palladium-Catalyzed 1,5-Substitution Reactions of 2-En-4-yne Acetates and Carbonates with Organoboronic Acids *J. Org. Chem.*, 76, 5959-5971, 2011.

- Ziyanak, F.; Kus, M.; Artok, L. Rhodium-Catalysed Alkoxycarbonylative Cyclisation Reactions of 1,6-Enynes *Adv. Synth. Catal.* 353, 6, 897, 2011.

- Akpınar, G. E.; Kuş, M.; Üçüncü, M.; Karakuş, E.; Artok, L. Palladium-Catalyzed Alkoxycarbonylation of (Z)-2-En-4-yn Carbonates Leading to 2,3,5-Trienoates *Org. Lett.* 13, 748, 2011.

- Artok, L.; Kus, M.; Ürer, B. N.; Türkmen, G.; Aksın-Artok, Ö. Rhodium Catalysed Chemo-and Stereoselective Arylative and Alkenylative Cyclisation Reactions of Unsymmetric Diynes Containing a Terminal Alkyne Moiety with Organoboronic Acids *Org.Biomol. Chem.* 8, 2060, 2010.

- Artok, L.; Kus, M.; Aksın-Artok, Ö.; Dege, F. N.; Özkılınç, F. Y. Rhodium Catalyzed Reaction of Internal Alkynes with Organoborons Under CO Atmosphere: A Product Tunable Reaction *Tetrahedron*, 65, 9125, 2009. - Kus, M.; Artok-Aksin, Ö.; Ziyanak, F.; Artok, L. Synthesis of Alpha-Beta-Unsaturated Ketones by Rhodium-Catalyzed Carbonylative Arylation of Internal Alkynes with Arylboronic Acids *Synlett*, 17, 2587, 2008

#### CONFERENCES

- 8th Asian-European Symposium on Metal-Mediated Efficient Organic Synthesis (AES-MMEOS 2014), Izmir Institute of Technology, İzmir, Turkey, 7 -10 September 2014. (Organizing Committee)

- Chemical Physics IX Congress, Izmir Institute of Technology, İzmir, Turkey, 14-16 October 2010. (Organizing Committee)

- EU-COST D40 (Innovative Catalysis: New Processes and Selectivities), Gazi University, Ankara, Turkey, 25-27 May 2010 .(Poster)

-Organometallic Chemistry and Cataylst, İnonü Universty, Malatya, Turkey, 16-17 May 2010 (Poster)

-XXII. National Chemistry Congress, Eastern Mediterranean University, Cyprus, 6-10 October 2008 (Oral Presentation)

-X. National Spectroscopy Congrees, Izmir Institute of Technology, İzmir, Turkey, 04-07 July 2007 (Organizing Commitee)